(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/031398 Al 27 February 2014 (27.02.2014) P O P C T

(51) International Patent Classification: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61L 33/06 (2006.01) A61M 25/01 (2006.01) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, A61L 27/14 (2006.01) A61F 2/82 (2006.01) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (21) International Application Number: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, PCT/US20 13/054841 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (22) International Filing Date: TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 14 August 2013 (14.08.2013) ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 61/684,947 20 August 2012 (20.08.2012) US TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 61/787,237 15 March 2013 (15.03.2013) US EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (71) Applicant: TICONA LLC [US/US]; 8040 Dixie High TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, way, Florence, KY 41042 (US). KM, ML, MR, NE, SN, TD, TG). (72) Inventors: HUFEN, Julia; Wallacher Str. 54, 47495 Declarations under Rule 4.17 : Rheinberg (DE). VERROCCHI, Anthony; 1260 Upland — as to applicant's entitlement to apply for and be granted a Avenue Unit #2, Covington, KY 4101 1 (US). WALKEN- patent (Rule 4.1 7(H)) HORST, Rainer; Meissheideweg 20, 45328 Melle (DE). — as to the applicant's entitlement to claim the priority of the (74) Agents: JOHNSTON, Jason W. et al; Dority & Manning, earlier application (Rule 4.1 7(in)) PA, PO Box 1449, Greenville, South Caroline 29602 (US). Published: (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, — with international search report (Art. 21(3)) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,

00 o o (54) Title: BIOMEDICAL DEVICES COMPRISING MOLDED POLYETHYLENE COMPONENTS (57) Abstract: A molded polyethylene component that comprises polyethylene having a melt flow index of about 3.5 g/10 min or greater as measured by ASTM D 1238 at 190°C/2 1.5 kg weight and having an ash content of about 500 ppm or less may be useful biomedical devices, including kits and methods relating thereto. BIOMEDICAL DEVICES COMPRISING MOLDED POLYETHYLENE COMPONENTS

BACKGROUND [0001] The present invention relates to molded polyethylene components for use in conjunction with biomedical devices, including methods relating thereto. [0002] Polyethylene is often used in conjunction with biomedical devices because of, inter alia, its chemical resistance, biocompatibility, low specific gravity relative to metals, and wear resistance. Typically, polyethylene, having a purity sufficient for use in biological environments (e.g., minimal concentration of residual catalyst), has a low melt flow index, and in some instances essentially no melt flow index. Due to the hardness of low melt flow index polyethylene, production of biomedical devices and components therefrom is typically achieved through machining methods. While machining fabrication methods may allow for high precision components capable of meeting tight tolerances, these methods generally have a low throughput and can produce significant waste of the polyethylene material, both of which increase the cost of manufacturing. Further, machine fabrication can require large capital investments in equipment. Accordingly, methods and compositions that enable higher throughput manufacturing, like molding, may be desirable in the production of polyethylene-based biomedical device components.

SUMMARY OF THE INVENTION [0003] The present invention relates to molded polyethylene components for use in conjunction with biomedical devices, including methods relating thereto. [0004] I n one embodiment, the present invention provides for a biomedical device that comprises a molded polyethylene component that comprises a polyethylene composition that comprises polyethylene having a melt flow index of about 3.5 g/10 min or greater as measured by ASTM D1238 at 190°C/21.5 kg weight and having an ash content of about 500 ppm or less. [0005] I n another embodiment, the present invention provides for a biomedical device that comprises a conduit that comprises at least one wall defining an internal volume, the at least one wall comprising polyethylene having a melt flow index of about 3.5 g/10 min or greater as measured by ASTM D1238 at 190°C/21.5 kg weight and having an ash content of about 500 ppm or less. [0006] I n yet another embodiment, the present invention provides for a method that comprises providing a polyethylene composition melt that comprises polyethylene having a melt flow index of about 3.5 g/10 min or greater as measured by ASTM D1238 at 190°C/21.5 kg weight and having an ash content of about 500 ppm or less; and extruding the polyethylene composition melt t o form a molded polyethylene component of a biomedical device. [0007] I n another embodiment, the present invention provides for a method that comprises providing a polyethylene composition melt that comprises polyethylene having a melt flow index of about 3.5 g/10 min or greater as measured by ASTM D1238 at 190°C/21.5 kg weight and having an ash content of about 500 ppm or less; and injection molding the polyethylene composition melt to form a molded polyethylene component of a biomedical device. [0008] I n yet another embodiment, the present invention provides for a method that comprises providing a component of a biomedical device; and substantially encasing the component in polyethylene having a melt flow index of about 3.5 g/10 min or greater as measured by ASTM D1238 at 190°C/21.5 kg weight and having an ash content of about 500 ppm or less. [0009] I n yet another embodiment, the present invention provides for a method that comprises polymerizing at least one olefin in the presence of a catalyst so as t o form polyethylene having a melt flow index of about 3.5 g/10 min or greater as measured by ASTM D1238 at 190°C/21.5 kg weight, the at least one olefin being selected from the group consisting of ethylene, propylene, and/or butylene, and any combination thereof; and treating the polyethylene to yield a treated polyethylene having an ash content of about 500 ppm or less. [0010] I n another embodiment, the present invention provides for a method that comprises providing a sheet comprising a polyethylene composition that comprises polyethylene having a melt flow index of about 3.5 g/10 min or greater as measured by ASTM D1238 at 190°C/21.5 kg weight and having an ash content of about 500 ppm or less; and thermoforming the sheet into a molded polyethylene component of a biomedical device. [0011] I n yet another embodiment, the present invention provides for a method that comprises providing a sheet comprising a polyethylene composition that comprises polyethylene having a melt flow index of about 3.5 g/10 min or greater as measured by ASTM D1238 at 190°C/21.5 kg weight and having an ash content of about 500 ppm or less; and shrink wrapping the sheet onto a portion of a biomedical device or component thereof. [0012] The features and advantages of the present invention will be readily apparent to those skilled in the art upon a reading of the description of the preferred embodiments that follows.

DETAILED DESCRIPTION [0013] The present invention relates to molded polyethylene components for use in conjunction with biomedical devices, including methods relating thereto. I n some instances, the molded polyethylene components may be biomedical devices themselves. [0014] The molded polyethylene components of the present invention for use in conjunction with biomedical devices may, in some embodiments, comprise polyethylene compositions with high purity that is melt flowable, thereby enabling the molded polyethylene components to be produced via molding and/or extruding methods. The ability to form a polyethylene component via these methods may advantageously enable faster production of high precision components as compared to machining methods. Molding method may also enable the production of complex and smaller components that are time and cost prohibitive if produced by machining methods. Further, the waste associated with manufacturing may be reduced as compared to machining methods. Accordingly, for at least these reasons, the ability to mold and/or extrude polyethylene components of the present invention for use in conjunction with biomedical devices as described herein may, in turn, reduce manufacturing costs, and consequently consumer costs, which especially in the biomedical sector may be especially advantageous. [0015] It should be noted that when "about" is provided at the beginning of a numerical list, "about" modifies each number of the numerical list. It should be noted that in some numerical listings of ranges, some lower limits listed may be greater than some upper limits listed. One skilled in the art will recognize that the selected subset will require the selection of an upper limit in excess of the selected lower limit. [0016] I n some embodiments, a biomedical device may comprise a molded polyethylene component of the present invention. A molded polyethylene component of the present invention may, in some embodiments, comprise a polyethylene composition that comprises a high-purity, melt-flowable polyethylene. It should be noted that the term "molded polyethylene component" is used herein for clarity and should not be seen as limiting as to how the polyethylene component is produced. As used herein, the terms "high- purity, melt-flowable polyethylene" and "HPMF polyethylene" refers to a composition that comprises polyethylene having a melt flow index of about 3.5 g/10 min or greater as measured by ASTM D1238 at 190°C/21.5 kg weight and having an ash content of about 500 ppm or less. It should be noted that as used herein "polyethylene" encompasses copolymers of ethylene with other olefinic monomers, e.g., propylene, butylene, and the like, including mixtures and blend polymers thereof. [0017] I n some embodiments, the HPMF polyethylene described herein of the molded polyethylene component of the present invention may have a melt flow index of about 3.5 g/10 min or greater, about 5 g/10 min or greater, or about 7 g/10 min or greater as measured by ASTM D1238 at 190°C/21.5 kg weight. I n some embodiments, the HPMF polyethylene described herein of the molded polyethylene component of the present invention may have a melt flow index ranging from a lower limit of about 3.5 g/10 min, 5 g/10 min, or 10 g/10 min to an upper limit of about 30 g/10 min, 25 g/10 min, 20 g/10 min, or 15 g/10 min as measured by ASTM D1238 at 190°C/21.5 kg weight. [0018] I n some embodiments, the HPMF polyethylene described herein of the molded polyethylene component of the present invention may have an ash content of about 500 ppm or less, about 250 ppm or less, about 100 ppm or less, 50 ppm or less, or 10 ppm or less. I n some embodiments, the HPMF polyethylene described herein of the molded polyethylene component of the present invention may have an ash content ranging from a lower limit of about 0.1 ppm, 1 ppm, 10 ppm, 25 ppm, 50 ppm, 75 ppm, 100 ppm, or 150 ppm to an upper limit of about 500 ppm, 400 ppm, 300 ppm, 250 ppm, 200 ppm, 150 ppm, 100 ppm, 50 ppm, or 10 ppm, and wherein the ash content may range from any lower limit to any upper limit and encompass any subset therebetween. [0019] I n some embodiments, the HPMF polyethylene described herein of the molded polyethylene component of the present invention may be compliant with USP Class IV and/or ISO 10993 standards at the filing date of this application. [0020] I n some embodiments, the HPMF polyethylene described herein of the molded polyethylene component of the present invention may be further characterized as having a specific gravity of about 0.93 g/cm 3 to about 0.97 g/cm 3. [0021] I n some embodiments, the HPMF polyethylene described herein of the molded polyethylene component of the present invention may have an average molecular weight ranging from a lower limit of about 30,000 g/mol, 50,000 g/mol, 100,000 g/mol, 250,000 g/mol, or 500,000 g/mol to an upper limit of about 2,500,000 g/mol, 2,000,000 g/mol, 1,000,000 g/mol, or 500,000 g/mol, and wherein the average molecular weight may range from any lower limit to any upper limit and encompass any range therebetween. Methods suitable for measuring the molecular weight of the HPMF polyethylene described herein include ASTM D4020. [0022] I n some embodiments, the HPMF polyethylene described herein of the molded polyethylene component of the present invention may have a molecular weight distribution that is multimodal (i.e., having more than one local maxima, e.g., bimodal, trimodal, and the like) with each mode (i.e., local maxima) being between a lower limit of about 30,000 g/mol, 50,000 g/mol, 100,000 g/mol, 250,000 g/mol, or 500,000 g/mol and an upper limit of about 2,500,000 g/mol, 2,000,000 g/mol, 1,000,000 g/mol, or 500,000 g/mol, and wherein each mode of the molecular weight distribution may range from any lower limit to any upper limit and encompass any range therebetween. [0023] I n some embodiments, the HPMF polyethylene described herein of the molded polyethylene component of the present invention may be crosslinked, which may be achieved by with chemical crosslinkers, e.g., peroxides or silanes, and/or with radiation (e.g., electron beam crosslinking). Crosslinking may, in some embodiments, be useful for, inter alia, tailoring the mechanical properties of the polyethylene compositions described herein (e.g., increasing at least some mechanical properties so as t o allow for molded polyethylene com ponents of the present invention to, in some embod iments, be usefu l in low load appl ications) . [0024] I n some embod iments, polyethylene compositions suita ble for use in conju nction with molded polyethylene com ponents of the present invention may com prise HPM F polyethylene descri bed herei n and optional ly further com prise ing red ients selected from second polymers, com pati bilizers, plasticizers, APIs, imag ing agents, add itives, and any com bination thereof. [0025] I n some embod iments, the polyethylene com positions for use in conj unction with molded polyethylene com ponents of the present invention may com prise HPM F polyethylene descri bed herei n and optiona lly com prise at least one second polymer. I n some insta nces, second polymers may be misci ble, pa rtia lly misci ble, or non-m isci ble with the HPM F polyethylene. [0026] Second polymers suitable for use in conj unction with polyethylene com positions descri bed herein may, in some embod iments, incl ude, but are not limited to, other polyethylenes (e.g., linear low density polyethylenes (LLDPE) and low density polyethylenes (LDPE)), polypropylenes, polybutylene, graft-mod ified olefi n polymers, chlori nated polyethylenes, thermoplastic vulca nizates, polyether ether ketone (PEEK), polyisoprenes, polyesters, polya mides, ethylene copolymers, ethylene vinyl acetate copolymers, ethylene vinyl-methacrylate copolymers, silicones, polyethylene glycols, polyethylene oxide (PEO), ethylene oxide- propylene oxide copolymers (incl ude block copolymers like PLU RONICS® (polyethylene oxide- polypropylene oxide- polyethylene oxide tri block polymers, avai la ble from BASF)), polyethylene- polypropylene glycol {e.g., poloxamer), carbomer, polyca rboph il, polyethylene im ine, polyu retha nes, polyacrylonitrile, styrene block copolymers, rubbers, ethylene-carboxyl ic acid copolymers, ethylene acrylate copolymers, polybutylene, polybutad iene, nylons, polyca rbonates, ethylene ethylacrylate polymers (EEA), ethylene styrene interpolymers (ESI), aliphatic polyesters, poly(lactic acid), poly(g lycol ic acid), poly(lactic-co-g lycol ic acid), poly(butylene succi nate), poly(ca prolactone), polya nhyd rides, poly(vi nyl alcohol), cel lu losics, chita ns, chitosa ns, cel lu lose esters, cel lulose acetate, nitrocel lulose, methyl cel lu lose, polyvi nyl pyrrol idone (PVP), hyd roxyal kyl cel luloses (e.g., hydroxypropyl cel lulose (HPC), hyd roxyethyl cel lulose (HEC), hyd roxymethyl cel lulose, and hyd roxypropyl methylcel lulose (HPMC)), carboxymethyl cel lulose, sod ium carboxymethyl cel lulose, methylcel lulose, hyd roxyethyl methylcel lulose, hydroxypropyl methylcellulose, polyacrylates, polyacrylamides, polymethacrylamides, polyphosphazines, polyoxazolidines, polyhydroxyalkylcarboxylic acids, alginic acids {e.g., carrageenate alginates, ammonium alginate, and sodium alginate), starch and starch derivatives, polysaccharides, carboxypolymethylene, and the like, any derivative thereof, any copolymer thereof, and any combination thereof. [0027] In some embodiments, second polymers for use in conjunction with the polyethylene compositions described herein may be absorbable. As used herein, the term "absorbable compositions" and the like refers to compositions that are capable of being absorbed by the local environment, where absorption may be of a complete composition or a component thereof (e.g., a polymer or a component thereof that may be produced if the polymer is degraded, e.g., by hydrolysis). As used herein, the term "bioabsorbable" and the like refers to absorbable compositions where the local environment is biological in nature, e.g., in vivo. The use of absorbable second polymers may, in some embodiments, allow for the formation of the pores and/or void spaces in situ. Further, the use of absorbable additional polymers may, in some embodiments, enhance the release of active pharmaceutical ingredients, described further herein. Suitable bioabsorbable second polymers for use in conjunction with the present invention may include, but are not limited to, aliphatic polyesters, poly(lactic acid), poly(glycolic acid), poly(lactic-co-glycolic acid), poly(butylene succinate), poly(caprolactone), polyanhydrides, poly(vinyl alcohol), starches, cellulosics, chitans, chitosans, cellulose esters, cellulose acetate, nitrocellulose, and the like, any derivative thereof, and any combination thereof. [0028] I n some embodiments, second polymers may be included in the polyethylene compositions described herein in an amount ranging from a lower limit of about 0.005%, 0.01%, 0 .1%, 0.5%, 1%, 2%, or 5% to an upper limit of about 50%, 25%, 10%, or 5% by weight of the polyethylene composition, wherein the amount may range from any lower limit to any upper limit and encompass any subset therebetween. The amount of second polymer may depend on a number of factors that include, inter alia, the biomedical device in which the molded polyethylene component will be utilized, the desired properties (e.g., strength) of the molded polyethylene component, the composition of the second polymer, and any additional ingredients utilized in conjunction with the polyethylene composition. [0029] I n some embodiments, the polyethylene compositions for use in conjunction with molded polyethylene components of the present invention may comprise HPMF polyethylene described herein and optionally comprise at least one plasticizer and/or compatibilizer. Plasticizers and/or compatibilizers may, in some embodiments, be useful for, inter alia, tailoring the mechanical properties of the polyethylene compositions described herein and/or aiding in the homogeneous incorporation of additional ingredients into the polyethylene compositions. Examples of plasticizers and/or compatibilizers suitable for use in conjunction with polyethylene compositions described herein may include, but are not limited to, polydimethylsiloxane, polyvinylbutyral, fluoropolymers, polyvinylidene fluoride, polybutadiene, polyisoprene, polyvinyl pyrrolidone, and the like, any derivative thereof, any copolymer thereof, and any combination thereof. [0030] I n some embodiments, plasticizers and/or compatibilizers may be included in polyethylene compositions described herein in an amount ranging from a lower limit of about 0.005%, 0.01%, 0.1%, 0.5%, 1%, 2%, or 5% to an upper limit of about 50%, 25%, 10%, or 5% by weight of the polyethylene composition, wherein the amount may range from any lower limit to any upper limit and encompass any subset therebetween. The amount of plasticizers and/or compatibilizers may depend on a number of factors that include, inter alia, the biomedical device in which the molded polyethylene component will be utilized, the desired properties (e.g., strength) of the molded polyethylene component, and any additional ingredients utilized in conjunction with the polyethylene composition. [0031] I n some embodiments, the polyethylene compositions for use in conjunction with molded polyethylene components of the present invention may comprise HPMF polyethylene described herein and optionally comprise at least one active pharmaceutical ingredient ("API"). It should be noted that the term "API" encompasses prodrugs. [0032] I n some embodiments, the APIs described herein may be dispersed in at least a portion of the polyethylene compositions described herein and/or disposed on at least a portion of a surface of the polyethylene compositions described herein. By way of nonlimiting example, a biomedical device (e.g., an artificial joint) may comprise a molded polyethylene component (e.g., a base-plate stem cap) that consists essentially of a polyethylene composition that comprises a HPMF polyethylene and an active pharmaceutical, like an anti-inflammatory. Additional nonlimiting examples of APIs suitable for use in conjunction with the polyethylene composition of molded polyethylene components of the present invention are described further herein. [0033] I n some embodiments, APIs may be included in polyethylene compositions herein in an amount ranging from a lower limit of about 0.005%, 0.01%, 0 .1%, 0.5%, 1%, or 2% to an upper limit of about 10%, 5%, or 2% by weight of the polyethylene composition described herein, wherein the amount may range from any lower limit to any upper limit and encompass any subset therebetween. The amount of APIs may depend on a number of factors that include, inter alia, the biomedical device in which the molded polyethylene component will be utilized and any additional ingredients utilized in conjunction with the polyethylene composition. [0034] I n some embodiments, the polyethylene compositions for use in conjunction with molded polyethylene components of the present invention may comprise HPMF polyethylene described herein and optionally comprise at least one imaging agent. As used herein, the term "imaging agent" refers to a molecule, compound, or particle that interacts with electromagnetic radiation to enable one to ascertain an image. [0035] I n some embodiments, the imaging agents described herein may be dispersed in at least a portion of the polyethylene compositions described herein and/or disposed on at least a portion of a surface of the polyethylene compositions described herein. [0036] Examples of imaging agents suitable for use in conjunction with the polyethylene compositions described herein may, in some embodiments, include, but are not limited to, magnetic resonance imaging agents (e.g., barium sulfate, iron oxide particles, gadolinium compounds, erbium compounds, gadolinium endofullerenes, and gadolinium endonanotubes), x-ray imaging agents (e.g., barium sulfate, iodine compounds, and iodine endonanotubes), ultrasound imaging agents (e.g., perfluorocarbons and air bubbles), near infrared imaging agents (e.g., carbon nanotubes, gold nanoparticles, silver nanoparticles, and gold nanoshells), bismuth compounds, tungsten compounds, and the like, and any combination thereof. [0037] I n some embodiments, imaging agents may be useful in monitoring the condition of the molded polyethylene component of the present invention (or polyethylene composition thereof) over the long-term. By way of nonlimiting example, an imaging agent disposed on the surface of the polyethylene compositions and/or dispersed in the polyethylene composition near the surface of the molded polyethylene component may be useful for noninvasively monitoring degradation (e.g., physical wear) of the molded polyethylene component. [0038] I n some embodiments, imaging agents may be included in polyethylene compositions described herein in an amount ranging from a lower limit of about 0.005%, 0.01%, 0 .1%, 0.5%, 1%, 2%, or 5% to an upper limit of about 25%, 10%, 5%, or 1% by weight of the polyethylene compositions described herein, wherein the amount may range from any lower limit to any upper limit and encompass any subset therebetween. The amount of imaging agents may depend on a number of factors that include, inter alia, the biomedical device in which the molded polyethylene component will be utilized and any additional ingredients utilized in conjunction with the polyethylene composition. [0039] I n some embodiments, the polyethylene compositions for use in conjunction with molded polyethylene components of the present invention may comprise HPMF polyethylene described herein and optionally comprise at least one additive. I n some embodiments, the additives may be dispersed in at least a portion of the polyethylene compositions described herein and/or disposed on at least a portion of a surface of the polyethylene compositions described herein. [0040] Examples of additives suitable for use in conjunction with the polyethylene compositions described herein may, in some embodiments, include, but are not limited to, antioxidants, reinforcing fillers, pigments and/or dyes, radioopaque fillers, lubricants, processing aids, light stabilizers, neutralizers, antiblocks, antifouling agents, and the like, and any combination thereof. [0041] Antioxidants may, in some embodiments, mitigate oxidation and/or chemical degradation of polyethylene compositions described herein during storage, transportation, and/or implementation (in vivo and/or ex vivo). Examples of antioxidants suitable for use in conjunction with the polyethylene compositions described herein may, in some embodiments, include, but are not limited to, ascorbic acid, glutathione, lipoic acid, uric acid, resveratrol, flavonoids, carotenes (e.g., beta-carotene), carotenoids, tocopherols (e.g., alpha-tocopherol), tocotrienols, ubiquinol, melatonin, secondary aromatic amines, benzofuranones, hindered phenols, polyphenols, hindered amines, organophosphorus compounds, thioesters, benzoates, lactones, hydroxylamines, and any combination thereof. [0042] Reinforcing fillers may, in some embodiments, inter alia, enhance the mechanical strength of polyethylene compositions described herein. Examples of reinforcing fillers suitable for use in conjunction with the polyethylene compositions described herein may, in some embodiments, include, but are not limited to, glass spheres, glass fibers, bioglass, graphite, aluminum powder, talc, chalk, silicates, carbonates, calcium carbonate, alumina trihydrate, marble dust, cement dust, clay, feldspar, fumed silica, alumina, magnesium oxide, magnesium hydroxide, antimony oxide, zinc oxide, barium sulfate, aluminum silicate, calcium silicate, titanium dioxide, titanates, glass microspheres, carbon fibers, metallic fibers, carbon nanotubes, wood flour, carbon black, and the like, and any combination thereof. [0043] Examples of pigments and/or dyes suitable for use in conjunction with polyethylene compositions described herein may, in some embodiments, include, but are not limited to, inorganic-based colorants, organic-based colorants, and the like, and any combination thereof. [0044] Examples of antifouling agents suitable for use in conjunction with polyethylene compositions described herein may, in some embodiments, include, but are not limited to, sulfoamides, penicillin, cephalosorins, carbapenems, quinolones, oxazolidones, quanternary ammonium compounds, nobel metals (e.g., silver, gold, copper, and the like), amine containing polymers, and the like, and any combination thereof. [0045] In some embodiments, any of the additives described herein may be included in polyethylene compositions described herein in an amount ranging from a lower limit of about 0.005%, 0.01%, 0 .1%, 0.5%, 1%, 2%, or 5% to an upper limit of about 50%, 25%, 10%, 5%, or 1% by weight of the polyethylene composition, wherein the amount may range from any lower limit to any upper limit and encompass any subset therebetween. The amount of additives may depend on a number of factors that include, inter alia, the biomedical device in which the molded polyethylene component will be utilized, the desired properties (e.g., strength) of the polyethylene composition, and any additional ingredients utilized in conjunction with the polyethylene composition. [0046] I n some embodiments, polyethylene compositions described herein may have a tensile modulus ranging from a lower limit of about 1 MPa, 10 MPa, 25 MPa, 50 MPa, 100 MPa, or 250 MPa to an upper limit of about 2500 MPa, 1500 MPa, 1000 MPa, 750 MPa, 500 MPa, or 250 MPa, and wherein the tensile modulus may range from any lower limit to any upper limit and encompass any subset therebetween. [0047] I n some embodiments, polyethylene compositions described herein may have a Young's modulus (elastic modulus) ranging from a lower limit of about 200 MPa, 500 MPa, 1000 MPa, or 1500 MPa to an upper limit of about 6000 MPa, 5000 MPa, 2500 MPa, or 1000 MPa, and wherein the Young's modulus may range from any lower limit to any upper limit and encompass any subset therebetween. [0048] I n some embodiments, polyethylene compositions suitable for use in conjunction with molded polyethylene components of the present invention may comprise HPMF polyethylene (according to any combination of a melt flow index described herein, an ash content described herein, and a specific gravity described herein) (which may, in some embodiments, be compliant with USP Class IV and/or ISO 10993 standards at the filing date of this application) and optionally further comprise ingredients selected from second polymers, compatibilizers, plasticizers, APIs, imaging agents, additives, and any combination thereof (including any combination thereof at concentrations described herein), and optionally have a tensile modulus and/or Young's modulus described herein. [0049] I n some embodiments, molded polyethylene components of the present invention may comprise polyethylene compositions described herein and optionally further comprise a reinforcing structure. I n some embodiments, the polyethylene compositions may be disposed on at least a portion of a surface of a reinforcing structure. Reinforcing structures may, in some embodiments, inter alia, enhance the mechanical strength of the molded polyethylene component of the present invention, enable post-production shaping of the molded polyethylene component of the present invention, enable securing of the molded polyethylene component within a biomedical device and/or t o another object (e.g., a bone), and any combination thereof. [0050] Reinforcing structures suitable for use in conjunction with molded polyethylene components of the present invention may, in some embodiments, comprise ultra high molecular weight polyethylene, metals {e.g., titanium), metal alloys (e.g., cobalt chromium alloys and trabecular metal), ceramics, glass, bioglass, and the like, and any combination thereof. Reinforcing structures suitable for use in conjunction with the molded polyethylene components of the present invention may, in some embodiments, be in the form of a rod, a tube, wire, mesh, a sheet, beads, and the like, and any hybrid thereof. [0051] I n some embodiments, the molded polyethylene components of the present invention may comprise a surface coating. It should be noted that the term "coating" does not imply 100% surface coverage. I n some embodiments, the surface coating may be a polymeric layer disposed on at least a portion of the surface of the molded polyethylene components. [0052] Polymers suitable for use in conjunction with surface layers described herein may include, but are not limited to, a second HPME polyethylene, a second polymer described herein, and any combination thereof. I n some embodiments, a surface layer may comprise a bioabsorbable polymer, e.g., those described herein. [0053] I n some embodiments, a surface layer {e.g., a polymeric layer) may be involved with at least one of: controlling the release profile of an API, providing burst release in the release profile of an API, delaying release of an API, and any combination thereof. [0054] I n some instances, the surface (or portion thereof) of the molded polyethylene component may be treated to enhance adhesion between the molded polyethylene component and the surface layer. Suitable treatments may include, but are not limited to, plasma treatment, corona treatment, and the like. [0055] I n some instances, the polyethylene composition may be adjusted to enhance adhesion between the molded polyethylene component and the surface layer, e.g., by inclusion of a second polymer. [0056] I n some embodiments, the molded polyethylene components of the present invention have a desired shape. As should be recognized by one of ordinary skill in the art, the desired shape may depend on, inter alia, the biomedical device in which the molded polyethylene components of the present invention are utilized. By way of nonlimiting example, in some embodiments, a molded polyethylene component, e.g., a sheath to a wire or a portion of a drug del ivery device, may be in the sha pe of a cond uit. By way of another non limiti ng example, in some embod iments, a molded polyethylene com ponent (e.g., an aneu rysm cla mp) may be in a more com plex shape that is desig ned for both movement and locki ng . By way of yet another nonl imiti ng exam ple, in some embod iments, a molded polyethylene com ponent (e.g., an ocu la r orbita l wall impla nt or tra nsdermal patch) may be in a shape similar to that of a sheet. By way of another nonl imiti ng example, in some embod iments, a molded polyethylene com ponent (e.g., cran io-maxi llofacial implant) may be in a shape similar to that of a bone or the like. [0057] I n some embodi ments, a molded polyethylene com ponent of the present invention may be non load-bea ring . [0058] I n some embod iments, molded polyethylene components of the present invention may be uti lized in assem bling biomed ica l devices. I n some embod iments, a biomed ica l device com prisi ng at least one molded polyethylene com ponent of the present invention may be a load- bea ring or nonload-bea ring biomed ica l device. As used herei n, the term " load-bea ring" refers to a com ponent, device, or materia l that is ca pable of mainta ining a structu ral load . For example, in biomed ical devices, a hip implant, a t ibia implant, a wrist or hand impla nt, and the like are considered load-beari ng biomedica l devices. [0059] Exa mples of biomed ica l devices that may com prise molded polyethylene com ponents of the present invention may, in some embod iments, incl ude, but are not limited to, chips, RFID tags, t ubing, pumps, feed ing t ubes, catheters, vascu la r catheters, prosthesis, inflatable balloons, stents, hea rt valves, neu rosti mulators, cochlear impla nts, cra nio- maxi llofacia l implants, synthetic ca rti lage, stomach rings, surgical instru ments, blood vessel cla mps, aneu rysm cla mps, spi nal plugs for use in conj unction with a joi nt fusion system, base plates for use in artificia l joi nts, muscle impla nts, nasopharyngea l impla nts, la ryngea l impla nts, drug del ivery devices, tra nsdermal patches, subderma l impla nts, oromucosa l inserts, intra uteri ne devices, intravag inal rings, denta l f ibers, and the like. [0060] I n some embod iments, molded polyethylene components of the present invention may be a cond uit that com prises at least one wall defin ing an interna l vol ume, the at least one wall com prisi ng polyethylene com positions descri bed herei n. [006 1] I n some embodi ments, a cond uit molded polyethylene com ponent may be desig ned to allow fluid to flow t hroug h the interna l vol ume. For exa mple, biomed ica l devices like pumps, t ubings, feed ing t ubes, catheters, vascular catheters, stents, hea rt valves, surgica l instru ments (e.g., surgica l suction instru ments), nasopha ryngeal impla nts, and la ryngea l impla nts may each com prise at least one condu it molded polyethylene component desig ned to allow flu id to flow throug h the interna l vol ume. [0062] I n some embodi ments, a cond uit molded polyethylene com ponent may have at least one wire disposed withi n the internal vol ume. By way of nonl imiting exam ple, in some embod iments, a biomed ica l device (e.g., a pacema ker) may com prise at least one wire havi ng a cond uit molded polyethylene com ponent disposed thereabout. [0063] I n some embod iments, molded polyethylene com ponents descri bed herei n may be the pri mary com position of a biomed ica l device (e.g., cranio-maxi llofacial impla nts) . I n some insta nces, the polyethylene com positions of the molded polyethylene com ponents may com prise HP F polyethylene and a bioabsorba ble polymer, such that when im plemented, the bioabsorba ble polymer is absorbed leavi ng voids in the polyethylene com position . [0064] I n some embod iments, molded polyethylene components of the present invention may substa ntia lly encase other components of a biomed ical device. I n some embod iments, the encasement may be such that when im pla nted in a patient the surrou ndi ng tissue may be pri marily exposed to the molded polyethylene com ponent. I n some embod iments, encasement may be achieved by over mold ing, thermoform ing, or shri nk wra ppi ng a polyethylene com position descri bed herei n at least partial ly about the other com ponents to be encased . I n some embodi ments, encasement may be achieved by form ing a molded polyethylene com ponent appropriately sized for placement of a biomed ica l device and/or com ponent thereof therei n. [0065] By way of non lim iti ng example, in some embod iments, a biomed ica l device, e.g., a coch lea r impla nt or an RFID tag, may be substa ntial ly encased in a molded polyethylene com ponent, such that the molded polyethylene com ponent resem bles a coati ng disposed substa ntial ly about the biomed ica l device. By way of another non limiti ng example, a biomed ical device, e.g., a pacemaker or a neu rosti mulator, may com prise a molded polyethylene com ponent that comprises a wire havi ng a coati ng disposed substantial ly thereabout, the coating comprising a polyethylene composition described herein. By way of another nonlimiting example, the power supply for a neurostimulator may comprise a molded polyethylene component substantially encasing the power supply, e.g., achieved by over molding, thermoforming, or shrink wrapping. [0066] I n some embodiments, molded polyethylene components described herein may be a drug delivery device or portion thereof. I n some embodiments, a transdermal patch may comprise a backing, a medicated layer, and a release layer (which may optionally comprise APIs), wherein the molded polyethylene component may be the mediciated layer and/or the release layer. By way of nonlimiting example, the medicated layer may be a molded polyethylene component (e.g., comprising HPMF polyethylene and an API) and the release layer may comprise a second polymer (e.g., an ethylene copolymer like ethylene vinyl acetate). I n some instances, the molded polyethylene component may comprise HPMF polyethylene and a second polymer. I n some instances, the medicated layer and the release layer may independently be molded polyethylene components with different compositions (e.g., different HPMF polyethylene, optionally blended with a second polymer, optionally comprising an API or another additive, and so on). [0067] Similar to the transdermal patch examples, other drug delivery devices may comprise molded polyethylene components. For example, a vaginal ring with a core similar t o the medicated layer above and the sheath similar to the release layer above. I n another example, a subdermal implant like a rod or sheet with a multi-layer structure may have at least one layer similar to the medicated layer and at least one layer similar to the release layer described above. [0068] Forming molded polyethylene components of the present invention into a desired shape may involve extruding, injection molding, blow molding, over molding, thermoforming, shrink wrapping, compression molding, casting, calendaring, near net shape molding, adhesive bonding, mechanical fastening, and the like, any hybrid thereof, and any combination thereof. [0069] I n some embodiments, forming molded polyethylene components of the present invention may involve extruding (or the like as described above) a polyethylene composition in melt form (i.e., a polyethylene composition melt) into a desired shape. I n some embodiments, a polyethylene com position melt suitable for use in form ing a molded polyethylene com ponent may com prise HP F polyethylene descri bed herei n and any suita ble optiona l ingred ients (e.g., second polymers, plasticizers, com pati bilizers, APIs, imag ing agents, add itives, and the like) . [0070] Temperatu res suitable for extrud ing (or the like as descri bed above) a polyethylene com position melt described herei n may, in some embod iments, range from a lower limit of about 60°C, 75°C, or 100°C to an upper limit of about 300°C, 250°C, 200°C, or 100°C, and wherei n the tem peratu re may range from any lower limit to any upper lim it and encompass any subset therebetween . It shou ld be noted that form ing methods that uti lize pressu re, like com pression mold ing, may, in some embod iments, ena ble form ing molded polyethylene com ponents of the present invention at lower tem peratu res and/or shorter t imes. [007 1] In some embod iments, form ing molded polyethylene com ponents of the present invention may involve extrud ing (or the like as descri bed above) a polyethylene composition melt onto at least a portion of a surface of a reinforci ng structu re described herein . [0072] In some embod iments, form ing molded polyethylene com ponents of the present invention may involve extrud ing (or the like as descri bed above) a polyethylene com position melt onto and/or at least partial ly about (e.g., to encase) other com ponents of a biomed ica l device (e.g., encasi ng cond uctive wires, applyi ng a surface layer to at least one side of a meta l plate, or substa ntia lly over mold ing a pacema ker) . [0073] In some embod iments, form ing molded polyethylene com ponents of the present invention may involve extrud ing (or the like as descri bed above) a polyethylene com position melt accord ing to any embod iments described herei n into a desi red sha pe and then treati ng the desi red sha pe with suita ble optional ingred ients (e.g., APIs, imag ing agents, add itives like antioxidants, dyes, and pigments, and the like) . Treati ng the desi red shape after form ing by polymer melt methods may, in some embod iments, be advantageously uti lized when the suitable optiona l ing red ients are tem peratu re sensitive (e.g., thermal ly deg rade) . Fu rther, treati ng after form ing by polymer com position melt methods may advantageously allow for placement of the suita ble optiona l ingred ients on at least a portion of the surface of the molded polyethylene component and/or dispersed in and near the surface of the molded polyethylene component. [0074] I n some embodiments, forming molded polyethylene components of the present invention may involve thermoforming (or the like as described above) a sheet comprising a polyethylene composition on or about at least a portion of a biomedical device or component thereof. I n some embodiments, thermoforming may involve compressing and heating a sheet (e.g., a molded polyethylene composition in sheet form) between at least two surfaces so as to form a biomedical device or component thereof. I n some embodiments, at least one of the surfaces may be at least a portion of a surface of a biomedical device or component thereof. Some embodiments may involve stretching and/or orienting a sheet in the longitudinal and/or transverse directions on or about a biomedical device or component thereof, the sheet comprising a polyethylene composition; and heating the sheet. [0075] I n some embodiments, the shape of biomedical devices may be manipulated after forming, e.g., minor changes to curvature to cranio- maxillofacial implants to match a desired bone structure. Shaping biomedical devices may be performed by applying heat and pressure to the biomedical device or component thereof. [0076] I n some instances forming molded polyethylene components may involve foaming the polyethylene composition. Foaming polyethylene compositions may be by any suitable method, e.g., with pore forming agents or fluid introduction during extrusion. [0077] Suitable pore forming compounds may include, but are not limited to, the bioabsorbable polymers described herein. Some embodiments may involve forming a molded polyethylene component from a polyethylene composition comprising a HPMF polyethylene and a bioabsorbable polymer; extracting a portion of the bioabsorbable polymer from the molded polyethylene component (e.g., via exposure to an aqueous fluid optionally with a desired pH, temperature, and salinity for extraction), thereby yielding a foamed polyethylene component. [0078] Some embodiments may involve extruding a polyethylene component from a polyethylene composition melt; and introducing a pore forming fluid into the polyethylene composition melt while extruding. Pore forming fluids suitable for foaming polyethylene compositions described herein may include, but are not limited to, air, an inert gas {e.g., helium, nitrogen, argon, carbon dioxide, n-butane, or isobutane), volatile liquids (e.g., water, methanol, or acetone), hydrocarbons {e.g., butane, isobutane, or pentane), halogenated hydrocarbons, perfluorocarbons, and the like, or any mixture thereof. In some embodiments, the pore forming fluids may be in a gas, liquid, subcritical, or supercritical form dissolved in the polyethylene composition melt. In some embodiments, pore forming fluids may serve to form the pores and as an agent, e.g., a perfluorocarbon gas that provides contrast in ultrasound imaging. I n some embodiments, pore forming fluids may be a volatile liquid that serves to form the pores and plasticize the polyethylene composition melt. In some embodiments, the amount of pore forming fluids added to a polyethylene composition melt may be at or below the saturation point of the pore forming fluids in the polyethylene composition melt. [0079] The parameters of introducing pore forming fluids into the polyethylene composition melt may be controlled to provide control over the diameter distribution of the pores of the resultant molded polyethylene component. Suitable parameters to adjust may include, but are not limited to, temperature of the polyethylene composition melt, temperature of the pore forming fluids, pressure of pore forming fluids, composition of the pore forming fluids, composition of the polyethylene composition melt, pressure of the polyethylene composition melt, conditions of extrusion, and any combination thereof. [0080] In some embodiments, biomedical devices comprising molded polyethylene components of the present invention may be implanted in and/or used in conjunction with the treatment of a patient. As used herein, the terms "subject" and "patient" are used interchangeably and refer to both human and nonhuman animals and insects. The term "nonhuman animals" as used herein includes all vertebrates, e.g., mammals and non-mammals, such as nonhuman primates, mice, rats, sheep, dogs, cats, horses, cows, chickens, amphibians, fish, reptiles, and the like. The term "insects" as used herein includes all arthropods, e.g., bees, flies, Drosophila flies, beetles, spiders, and the like. [0081] In some embodiments, molded polyethylene components of the present invention may be included in a kit that also includes a set of instructions. By way of nonlimiting example, a conduit molded polyethylene component, e.g., a tubing or a catheter, may be included in a kit along with a set of instructions for how to properly utilize the conduit molded polyethylene component, e.g., installing the tubing into biomedical device like a pump or inserting the catheter into a patient. [0082] I n some embodiments, molded polyethylene components of the present invention may comprise polyethylene compositions that comprise HPMF polyethylene (according t o any combination of a melt flow index described herein, an ash content described herein, and a specific gravity described herein) (which may, in some embodiments, be compliant with USP Class IV and/or ISO 10993 standards at the filing date of this application) and optionally further comprise ingredients selected from second polymers, compatibilizers, plasticizers, APIs, imaging agents, additives, and any combination thereof (including any combination thereof at concentrations described herein), and optionally have a tensile modulus and/or Young's modulus described herein, and the molded polyethylene components may optionally further comprise a reinforcing structure, have a desired shape, and be nonload-bearing. Such molded polyethylene components may be a biomedical device or be a component of a biomedical device. Such a biomedical device may, in some embodiments, be included in a kit and/or used for treating a patient, which may include implantation. Such molded polyethylene components may be formed according to any method or hybrid of methods described herein. I . High-Purity, Melt-Flowable Polyethylene [0083] As described above, the terms "high-purity, melt-flowable polyethylene" and "HPMF polyethylene," as used herein, refer t o polyethylene having a melt flow index of about 3.5 g/10 min or greater as measured by ASTM D1238 at 190°C/21.5 kg weight and having an ash content of about 500 ppm or less. [0084] Some embodiments of the present invention may involve producing the HPMF polyethylene described herein. I n some embodiments, producing the HPMF polyethylene described herein may involve polymerizing at least one olefin (e.g., comprising ethylene and optionally at least one of propylene and/or butylene) so as t o yield polyethylene having a melt flow index of about 3.5 g/10 min or greater as measured by ASTM D1238 at 190°C/21.5 kg weight, and then treating the polyethylene so as to yield HPMF polyethylene. [0085] I n some embodiments, the polymerization of at least one olefin may be carried out in suspension at low pressure and temperature in one or multiple steps in a continuous, batch, or hybrid process. I n some embodiments, polymerizing the at least one olefin may optionally be performed in the presence of at least one of: molar mass regulators, catalysts (e.g., titanium catalysts, aluminum/titanium catalysts, metallocenes, post metallocenes, and alumoxane), supported catalysts, organoaluminum compounds, hydrogen, anti-fouling agents, anti-static agents, and the like, and any combination thereof. [0086] I n some embodiments, the melt flow index of the polyethylene produced may be manipulated by, inter alia, the concentration and composition of the materials/compounds present during reaction (e.g., the at least one olefin, molar mass regulators, catalysts, organoaluminum compounds, hydrogen, and the like), the polymerization temperature, the catalyst, the composition of the solvents used, and any combination thereof. [0087] I n some embodiments, the at least one olefin may be present at a partial pressure of about 10 MPa or less. I n some embodiments, the at least one olefin may be present in a polymerization reaction at a partial pressure ranging from a lower limit of about 0.01 MPa, 0.05 MPa, 0.1 MPa, or 0.5 MPa t o an upper limit of about 10 MPa, 7 MPa, 5 MPa, or 3 MPa, and wherein the partial pressure of the at least one olefin may range from any lower limit to any upper limit and encompass any subset therebetween. [0088] I n some embodiments, the polymerization may be performed in the presence of hydrogen such that the partial pressure ratio of the at least one olefin to hydrogen ranges from a lower limit of about 0.01: 1, 0.05: 1, 0 . 1 : 1, 5 : 1, 10: 1, or 25: 1 to an upper limit of about 100: 1, 75: 1, or 50: 1, and wherein the ratio may range from any lower limit to any upper limit and encompass any subset therebetween. [0089] I n some embodiments, the polymerization may be performed at a temperature ranging from a lower limit of about 30°C, 50°C, or 70°C to an upper limit of about 130°C, 100°C, or 90°C, and wherein the temperature may range from any lower limit to any upper limit and encompass any subset therebetween. [0090] Solvents suitable for use in conjunction with polymerization reactions described herein may include, but are not limited to, butane, pentane, hexane, cyclohexene, octane, nonane, decane, isomers thereof, and the like, and any combination thereof. [0091] I n some embodiments, after polymerization, treating the polyethylene so as to yield the HPMF polyethylene may be achieved by treatment with at least one of: steam, an inert solvent the catalyst is at least partially soluble in (e.g., an acid, acetone, water, and a halogenated solvent), and the like, and any combination thereof, concurrently or in series. I n some embodiments, the inert solvent may be chosen based on, inter alia, the molded polyethylene component to be produced with the HPMF polyethylene. For example, a halogenated solvent may be avoided or used early in a series of treatments in the production of HPMF polyethylene so as to reduce the potential for halogenated solvent contamination in the molded polyethylene components for in vivo applications. [0092] I n some embodiments, treating may further comprise elevated temperatures and/or reduced pressures to remove any reaction solvents and/or inert solvents described herein. [0093] I n some embodiments, the treating may be for a prolonged period of time so as to yield a HPMF polyethylene with an ash content of about 500 ppm or less, about 250 ppm or less, about 100 ppm or less, or most preferably about 50 ppm or less. II. Active Pharmaceutical Ingredients [0094] Active pharmaceutical ingredients ("APIs") for use in conjunction with the molded polyethylene components of the present invention may include, but are not limited to, therapeutic agents, antibiotics, antifungals, active biologicals, antitoxins, antigens, nutritional supplements, nutraceuticals, and the like, any pro-version thereof, and any combination thereof. [0095] Examples of suitable therapeutic agents for use in conjunction with the molded polyethylene components of present invention may include, but are not limited to, 16-alpha fluoroestradiol, 16-alpha-gitoxin, 16-epiestriol, 17- alpha dihydroequilenin, 17-alpha estradiol, 17-beta estradiol, 17-hydroxy progesterone, 1-alpha-hydroxyvitamin D2, 1-dodecpyrrolidinone, 20-epi-l,25 dihydroxyvitamin D3, 22-oxacalcitriol, 2CW, 2'-nor-cGMP, 3-isobutyl GABA, 5- ethynyluracil, 6-FUDCA, 7-methoxytacrine, abamectin, abanoquil, abcizimab (commercially available as REOPRO® from Eli Lilly and Company), abecarnil, abiraterone, ablukast, ablukast sodium, acadesine, acamprosate, acarbose, acebutolol, acecamide hydrochloride, aceclidine, aceclofenae, acedapsone, aceglutamide aluminum, acemannan, acenocoumarol, acetaminophen, acetazolamide, acetohexamide, acetohydroxamic acid, acetomepregenol, acetophenazine maleate, acetosulfone sodium, acetylcholine chloride, acetylcysteine, acetyl-L-carnitine, acetylmethadol, acifran, acipimox, acitemate, acitretin, acivicin, aclarubicin, aclatonium, acodazole hydrochloride, aconiazide, acrisorcin, acrivastine, acronine, actisomide, actodigin, acyclovir, acylfulvene, adafenoxate, adalimumab (commercially available as HUMIRA® from Abbott Laboratories), adapalene, adatanserin, adatanserin hydrochloride, adecypenol, adefovir, adelmidrol, ademetionine, adenosine, adinazolam, adipheinine hydrochloride, adiposin, adozelesin, adrafinil, adrenalone, airbutamine, alacepril, alamecin, alanine, alaproclate, alaptide, albendazole, albolabrin, albuterol (commercially available as VENTOLIN® from GlaxoSmithKline), albutoin, alclofenae, alclometasone dipropionate, aluminum chlorhydroxyallantoinate (commercially available as ALCOLOXA® from TRI-K Industries, Inc.), aldecalmycin, aldesleukin, aldioxa, alendronate sodium (commercially available as FOSAMAX® from Merck), alendronic acid, alentemol, alentemol hydrobromide, aletamine hydrochloride, aleuronium chloride, alexidine, alfacalcidol, alfentanil hydrochloride, alfuzosin, algestone acetonide, alglucerase, aliflurane, alinastine, alipamide, allantoin, allobarbital, allopurinol, a tachy-kinins (TK) antagonist, alonimid, alosetron, alosetron hydrochloride, alovudine, alpertine, alpha amylase, alpha idosone, alpidem, alprazolam (commercially available as XANAX® from Pfizer, Inc.), alprenolol hydrochloride, alprenoxime hydrochloride, alprostadil, alrestatin sodium, altanserin tartrate, alteplase, althiazide, altretamine, altromycin B, alverinc citrate, alvircept sudotox, amadinone acetate, amantadine hydrochloride, ambamustine, ambomycin, ambruticin, ambuphylline, ambuside, amcinafal, amcinonide, amdinocillin, amdinocillin pivoxil, amedalin hydrochloride, amelometasone, ameltolide, amesergide, ametantrone acetate, amezinium metilsulfate, amfebutamone, amfenac sodium, amflutizole, amicycline, amidephrine mesylate, amidox, amifloxacin, amifostine, amikacin, amiloride hydrochloride, aminacrine hydrochloride, aminobenzoate potassium, aminobenzoate sodium, aminocaproic acid, aminoglutethimide, aminohippurate sodium, aminolevulinic acid, aminophylline, aminorex, aminosalicylate sodium, aminosalicylic acid, amiodarone, amiprilose hydrochloride, amiquinsin hydrochloride, amisulpride, amitraz, amitriptyline hydrochloride, amlexanox, amlodipine, amobarbital sodium, amodiaquine, amodiaquine hydrochloride, amorolfine, amoxapine, amoxicillin, amphecloral, amphetamine sulfate, amphomycin, amphotericin B, ampicillin, ampiroxicam, ampyzine sulfate, amquinate, amrinone, aminone, amrubicin, amsacrine, amythiamicin, anagestone acetate, anagrelide, anakinra, ananain, anaritide, anaritide acetate, anastrozole (commercially available as ARIMIDEX® from AstraZeneca), anazolene sodium, ancrod, andrographolide, androstenedione, angiogenesis inhibitors, angiotensin amide, anidoxime, anileridine, anilopam hydrochloride, aniracetam, anirolac, anisotropine methylbromide, anistreplase, anitrazafen, anordrin, antagonist D, antagonist G, antarelix, antazoline phosphate, anthelmycin, anthralin, anthramycin, antiandrogen, antihemophilic factor (commercially available as XYNTHA® from Pfizer, Inc.), acedapsone, felbamate, antiestrogen, antineoplaston, antipyrine, antisense oligonucleotides, apadoline, apafant, apalcillin sodium, apaxifylline, apazone, aphidicolin glycinate, apixifylline, apomorphine hydrochloride, apraclonidine, apraclonidine hydrochloride, apramycin, aprindine, aprindine hydrochloride, aprosulate sodium, aprotinin, aptazapine maleate, aptiganel, apurinic acid, apurinic acid, aranidipine, aranotin, arbaprostil, arbekicin, 1- methyl-2-((phenylthio) methyl)-3-carbethoxy-4-((dimethylamino) methyl)-5- hydroxy-6-bromindole (commercially available as ARBIDOL® from Masterlek), arbutamine hydrochloride, arclofenin, ardeparin sodium, (2R,4R)-l-[(2S)-5- (diaminomethylideneamino) -2-[[(3R)-3-methyl-l,2,3,4-tetrahydroquinolin-8-yl] sulfonylamino] pentanoyl]-4-methyl-piperidine-2-carboxylic acid (commercially available as ARGATROBAN® from GlaxoSmithKline), arginine, argipressin tannate, arildone, aripiprazol, arotinolol, arpinocid, arteflene, artilide fumarate, asimadoline, aspalatone, asparaginase, aspartic acid, aspartocin, asperfuran, aspirin, aspoxicillin, asprelin, astemizole, astromicin sulfate, asulacrine, atamestane, atenolol, atevirdine, atipamezole, atiprosin maleate, atolide, atorvastatin (commercially available as LIPITOR® from Pfizer, Inc.), atosiban, atovaquone, atpenin B, atracurium besylate, atrimustine, atrinositol, atromentin, atropine, auranofin, aureobasidin A, aurothioglucose, avilamycin, avoparcin, avridine, nizatidine (commercially available as AXID® from GlaxoSmithKline), axinastatin 1, axinastatin 2, axinastatin 3, azabon, azacitidinie, azaclorzine hydrochloride, azaconazole, azadirachtine, azalanstat dihydrochloride, azaloxan fumarate, azanator maleate, azanidazole, azaperone, azaribine, azaserine, azasetron, azatadine maleate, azathioprine, azathioprine sodium, azatoxin, azatyrosine, azelaic acid, azelastine, azelnidipine, azepindole, azetepa, azimilide, azithromycin, azlocillin, azolimine, azosemide, azotomycin, aztreonam, azumolene sodium, bacampicillin hydrochloride, baccatin III, bacitracin, baclofen, bacoside A, bacoside B, bactobolamine, balanol, balazipone, balhimycin, balofloxacin, balsalazide, bambermycins, bambuterol, bamethan sulfate, bamifylline hydrochloride, bamidazole, baohuoside 1, barmastine, barnidipine, basifungin, batanopride hydrochloride, batebulast, batelapine maleate, batimastat, beauvericin, becanthone hydrochloride, becaplermin, becliconazole, beclomethasone dipropionate, befloxatone, beinserazide, belfosdil, belladonna, beloxamide, bemesetron, bemitradine, bemoradan, benapryzine hydrochloride, benazepril hydrochloride, benazeprilat, bendacalol mesylate, bendazac, bendroflumethiazide, benflumetol, benidipine, benorterone, benoxaprofen, benoxaprofen, benoxinate hydrochloride, benperidol, bentazepam, bentiromide, benurestat, benzbromarone, benzethonium chloride, benzetimide hydrochloride, benzilonium bromide, benzindopyrine hydrochloride, benzisoxazole, benzocaine, benzochlorins, benzoctamine hydrochloride, benzodepa, benzoidazoxan, benzonatate, benzoyl peroxide, benzoylpas calcium, benzoylstaurosporine, benzquinamide, benzthiazide, benztropine, benztropine mesylate, benzydamine hydrochloride, benzylpenicilloyl polylysine, bepridil, bepridil hydrochloride, beractant, beraprost, berefrine, berlafenone, bertosamil, berythromycin, besipirdine, beta-alethine, betaclamycin B, betamethasone, betamipron, betaxolol, betaxolol hydrochloride, bethanechol chloride, bethanidine sulfate, betulinic acid, bevacizumab (commercially available as AVASTIN® available from Genenetech), bevantolol, bevantolol hydrochloride, bezafibrate, bFGF inhibitor, bialamicol hydrochloride, biapenem, bicalutamide, bicifadine hydrochloride, biclodil hydrochloride, bidisomide, bifemelane, bifonazole, bimakalim, bimithil, bindarit, biniramycin, binospirone, bioxalomycin alpha2, bipenamol hydrochloride, biperiden, biphenamine hydrochloride, biriperone, bisantrene, bisaramil, bisaziridinylspermine, bis-benzimidazole A, bis- benzimidazole B, bisnafide, bisobrin lactate, bisoprolol, bispyrithione magsulfex, bistramide D, bistramide K, bistratene A, bithionolate sodium, bitolterol besylate, bivalirudin, bizelesin, bleomycin sulfate, bolandiol dipropionate, bolasterone, boldenone undecylenate, boldine, bolenol, bolmantalate, bopindolol, bosentan, boxidine, brefeldin, breflate, brequinar sodium, bretazenil, bretylium bosylate, brifentanil hydrochloride, brimonidine, brinolase, brocresine, brocrinat, brofoxine, bromadoline maleate, bromazepam, bromchlorenone, bromelains, bromfenac, brominidione, bromocriptine, bromodiphenhydramine hydrochloride, bromoxamide, bromperidol, bromperidol decanoate, brompheniramine baleate, broperamole, bropirimine, brotizolam, bucamide maleate, bucindolol, buclizine hydrochloride, bucromarone, budesonide (commercially available as RHINOCORT® and ENTOCORT® from AstraZeneca), budipine, budotitane, buformin, bumetamide, bunaprolast, bunazosin, bunolol hydrochloride, bupicomide, bupivacaine hydrochloride, buprenorphine hydrochloride, bupropion hydrochloride, buramate, buserelin acetate, buspirone hydrochloride, busulfan, butabarbital, butacetin, butaclamol hydrochloride, butalbital, butamben, butamirate citrate, butaperazine, butaprost, butedronate tetrasodium, butenafine, buterizine, buthionine sulfoximine, butikacin, butilfenin, butirosin sulfate, butixirate, butixocort propionate, butoconazole nitrate, butonate, butopamine, butoprozine hydrochloride, butorphanol, butoxamine hydrochloride, butriptyline hydrochloride, cactinomycin, cadexomer iodine, caffeine, calanolide A, calcifediol, calcipotriene, calcipotriol, calcitonin, calcitriol, calcium undecylenate, calphostin C, calusterone, cambendazole, camonagrel, camptothecin derivatives, canarypox IL-2, candesartan, candicidin, candoxatril, candoxatrilat, caniglibose, canrenoate potassium, canrenone, capecitabine, capobenate sodium, capobenic acid, capreomycin sulfate, capromab, capsaicin, captopril, capuride, caracemide, carbachol, carbadox, carbamazepine, carbamide peroxide, carbantel lauryl sulfate, carbaspirin calcium, carbazeran, carbazomycin C, carbenicillin potassium, carbenoxolone sodium, carbetimer, carbetocin, carbidopa, carbidopa-levodopa, carbinoxamine maleate, carbiphene hydrochloride, carbocloral, carbocysteine, carbol-fuchsin, carboplatin, carboprost, carbovir, carboxamide-amino-triazole, carboxyamidotriazole, carboxymethylated beta-l,3-glucan, carbuterol hydrochloride, CaRest M3, carfentanil citrate, carisoprodol, carmantadine, carmustine, CARN 700, camidazole, caroxazone, carperitide, carphenazine maleate, carprofen, carsatrin succinate, cartazolate, carteolol, carteolol hydrochloride, cartilage derived inhibitor, carubicin hydrochloride, carumonam sodium, carvedilol, carvotroline, carvotroline hydrochloride, carzelesin, casein kinase inhibitors (ICOS), castanospermine, caurumonam, cebaracetam, cecropin B, cedefingol, cefaclor, cefadroxil, cefamandole, cefaparole, cefatrizine, cefazaflur sodium, cefazolin, cefbuperazone, cefcapene pivoxil, cefdaloxime pentexil tosilate, cefdinir, cefditoren pivoxil, cefepime, cefetamet, cefetecol, cefixime, cefluprenam, cefinenoxime hydrochloride, cefinetazole, cefminlox, cefodizime, cefonicid sodium, cefoperazone sodium, ceforamide, cefoselis, cefotaxime sodium, cefotetan, cefotiam, cefoxitin, cefozopran, cefpimizole, cefpiramide, cefpirome, cefpodoxime proxetil, cefprozil, cefroxadine, cefsulodin, ceftazidime, cefteram, ceftibuten, ceftizoxime sodium, ceftriaxone, cefuroxime, celastrol, celikalim, celiprolol, cepacidiine A, cephacetrile sodium, cephalexin, cephaloglycin, cephaloridine, cephalothin sodium, cephapirin sodium, cephradine, cericlamine, cerivastatin, ceronapril, certoparin sodium, ceruletide, cetaben sodium, cetalkonium chloride, cetamolol hydrochloride, cetiedil, cetirizine, cetophenicol, cetraxate hydrochloride, cetrorelix, cetuximab (commercially available as ERBITUX® from Eli Lilly and Company), cetylpyridinium chloride, chenodiol, chlophedianol hydrochloride, chloral betaine, chlorambucil, chloramphenicol, chlordantoin, chlordiazepoxide, chlorhexidine gluconate, chlorins, chlormadinone acetate, chloroorienticin A, chloroprocaine hydrochloride, chloropropamide, chloroquine, chloroquinoxaline sulfonamide, chlorothiazide, chlorotrianisene, chloroxine, chloroxylenol, chlorphenesin carbamate, chlorpheniramine maleate, chlorpromazine, chlorpropamide, chlorprothixene, chlortetracycline bisulfate, chlorthalidone, chlorzoxazone, cholestyramine resin, chromonar hydrochloride, cibenzoline, cicaprost, ciclafrine hydrochloride, ciclazindol, ciclesonide, cicletanine, ciclopirox, cicloprofen, cicloprolol, cidofovir, cidoxepin hydrochloride, cifenline, ciglitazone, ciladopa hydrochloride, cilansetron, cilastatin sodium, cilazapril, cilnidipine, cilobamine mesylate, cilobradine, cilofungin, cilostazol, cimaterol, cimetidine, cimetropium bromide, cinalukast, cinanserin hydrochloride, cinepazet maleate, cinflumide, cingestol, cinitapride, cinnamedrine, cinnarizine, cinolazepam, cinoxacin, cinperene, cinromide, cintazone, cintriamide, cioteronel, cipamfylline, ciprefadol succinate, ciprocinonide, ciprofibrate, ciprofloxacin, ciprostene, ciramadol, cirolemycin, cisapride, cisatracurium besilate, cisconazole, cisplatin, cis-porphyrin, cistinexine, citalopram, citenamide, citicoline, citreamicin alpha, cladribine, clamoxyquin hydrochloride, clarithromycin, clausenamide, clavulanate potassium, clazolam, clazolimine, clebopride, clemastine, Clentiazem maleate, clidinium bromide, clinafloxacin, clindamycin, clioquinol, clioxamide, cliprofen, clobazam, clobetasol propionate, clobetasone butyrate, clocortolone acetate, clodanolene, clodazon hydrochloride, clodronic acid, clof azimine, clofibrate, clofilium phosphate, clogestone acetate, clomacran phosphate, clomegestone acetate, clometherone, clomethiazole, clomifene analogues, clominorex, clomiphene, clomipramine hydrochloride, clonazepam, clonidine, clonitrate, clonixeril, clonixin, clopamide, clopenthixol, cloperidone hydrochloride, clopidogrel (commercially available as PLAVIX® from Bristol-Myers Squibb and Sanofi Pharmaceuticals), clopimozide, clopipazan mesylate, clopirac, cloprednol, cloprostenol sodium, clorazepate dipotassium, clorethate, clorexolone, cloroperone hydrochloride, clorprenaline hydrochloride, clorsulon, clortermine hydrochloride, closantel, closiramine aceturate, clothiapine, clothixamide maleate cloticasone propionate, clotrimazole, cloxacillin benzathine, cloxyquin, clozapine, cocaine, coccidioidin, codeine, codoxime, colchicine, colestimide, colestipol hydrochloride, colestolone, colforsin, colfosceril palmitate, colistimethate sodium, colistin sulfate, collismycin A, collismycin B, colterol mesylate, combretastatin A4, combretastatin analogue, complestatin, conagenin, conorphone hydrochloride, contignasterol, contortrostatin, cormethasone acetate, corticorelin ovine triflutate, corticotropin, cortisone acetate, cortivazol, cortodoxone, cosalane, costatolide, cosyntropin, cotinine, warfarin (commercially available as COUMADIN® from Bristol-Myers Squibb), coumermycin, coumarins, crambescidin 816, crilvastatin, crisnatol, cromitrile sodium, cromolyn sodium, crotamiton, cryptophycin 8, cucumariosid, cuprimyxin, curacin A, curdlan sulfate, zinc hyaluran (commercially available as CURIOSIN® from Gedeon Richter), cyclacillin, cyclazocine, cyclazosin, cyclic HPMPC, cyclindole, cycliramine maleate, cyclizine, cyclobendazole, cyclobenzaprine, cyclobut A, cyclobut G, cyclocapron, cycloguanil pamoate, cycloheximide, cyclopentanthraquinones, cyclopenthiazide, cyclopentolate hydrochloride, cyclophenazine hydrochloride, cyclophosphamide, cycloplatam, cyclopropane, cycloserine, cyclosin, cyclosporine, cyclothialidine, cyclothiazide, cyclothiazomycin, cyheptamide, cypemycin, cypenamine hydrochloride, cyprazepam, cyproheptadine hydrochloride, cyprolidol hydrochloride, cyproterone, cyproximide, cysteamine, cysteine hydrochloride, cystine, cytarabine, cytarabine hydrochloride, cytarabine ocfosfate, cytochalasin B, cytolytic factor, cytostatin, dabigatran, dacarbazine, dacliximab, dactimicin, dactinomycin, daidzein, daledalin tosylate, dalfopristin, dalteparin sodium, daltroban, dalvastatin, danaparoid, danazol, dantrolene, daphlnodorin A, dapiprazole, dapitant, dapoxetine hydrochloride, dapsone, daptomycin, darglitazone sodium, darifenacin, darlucin A, darodipine, darsidomine, darusentan, daunorubicin hydrochloride, dazadrol maleate, dazepinil hydrochloride, dazmegrel, dazopride fumarate, dazoxiben hydrochloride, debrisoquin sulfate, decitabine, deferiprone, deflazacort, dehydrocholic acid, dehydrodidemnin B, dehydroepiandrosterone, delapril, delapril hydrochloride, delavirdine mesylate, delequamine, delfaprazine, delmadinone acetate, delmopinol, delphinidin, demecarium bromide, demeclocycline, demecycline, demoxepam, denofungin, deoxypyridinoline, 2-propylpentanoic acid (commercially available as DEPAKOTE® from Abbott), deprodone, deprostil, depsidomycin, deramciclane, dermatan sulfate, desciclovir, descinolone acetonide, desflurane, desipramine hydrochloride, desirudin, deslanoside, deslorelin, desmopressin, desogestrel, desonide, desoximetasone, desoxoamiodarone, desoxycorticosterone acetate, detajmium bitartrate, deterenol hydrochloride, detirelix acetate, devazepide, dexamethasone, dexamisole, dexbrompheniramine maleate, dexchlorpheniramine maleate, dexclamol hydrochloride, dexetimide, dexfenfluramine hydrochloride, dexifosfamide, deximafen, dexivacaine, dexketoprofen, dexloxiglumide, dexmedetomidine, dexormaplatin, dexoxadrol hydrochloride, dexpanthenol, dexpemedolac, dexpropranolol hydrochloride, dexrazoxane, dexsotalol, dextrin 2-sulphate, dextroamphetamine, dextromethorphan, dextrorphan hydrochloride, dextrothyroxine sodium, dexverapamil, dezaguanine, dezinamide, dezocine, diacetolol hydrochloride, diamocaine cyclamate, diapamide, diatrizoate meglumine, diatrizoic acid, diaveridine, diazepam, diaziquone, diazoxide, dibenzepin hydrochloride, dibenzothiophene, dibucaine, dichliorvos, dichloralphenazone, dichlorphenamide, dicirenone, diclofenac sodium, dicloxacillin, dicranin, dicumarol, dicyclomine hydrochloride, didanosine, didemnin B, didox, dienestrol, dienogest, diethylcarbamazine citrate, diethylhomospermine, diethylnorspermine, diethylpropion hydrochloride, diethylstilbestrol, difenoximide hydrochloride, difenoxin, diflorasone diacetate, difloxacin hydrochloride, difluanine hydrochloride, diflucortolone, diflumidone sodium, diflunisal, difluprednate, diftalone, digitalis, digitoxin, digoxin, dihexyverine hydrochloride, dihydrexidine, dihydro-5-azacytidine, dihydrocodeine bitartrate, dihydroergotamine mesylate, hihydroestosterone, dihydrostreptomycin sulfate, dihydrotachysterol, dihydrotaxol, phenytoin (commercially available as DILANTIN® from Parke, Davis & Company), dilevalol hydrochloride, diltiazem hydrochloride, dimefadane, dimefline hydrochloride, dimenhydrinate, dimercaprol, dimethadione, dimethindene maleate, dimethisterone, dimethyl prostaglandin Al, dimethyl sulfoxide, dimethylhomospermine, dimiracetam, dimoxamine hydrochloride, dinoprost, dinoprostone, dioxadrol hydrochloride, dioxamycin, diphenhydramine citrate, diphenidol, diphenoxylate hydrochloride, diphenyl spiromustine, dipivefin hydrochloride, dipivefrin, dipliencyprone, diprafenone, dipropylnorspermine, dipyridamole, dipyrithione, dipyrone, dirithromycin, discodermolide, disobutamide, disofenin, disopyramide, disoxaril, disulfuram, ditekiren, divalproex sodium, dizocilpine maleate, dobutamine, docarpamine, docebenone, docetaxel, doconazole, docosanol, dofetilide, dolasetron, drotrecogin alfa (commercially available as XIGRIS® from Eli Lilly and Company), duloxetine hydrochloride (commercially available as CYMBALTA® from Eli Lilly and Company), ebastine, ebiratide, ebrotidine, ebselen, ecabapide, ecabet, ecadotril, ecdisteron, echicetin, echistatin, echothiophate iodide, eclanamine maleate, eclazolast, ecomustine, econazole, ecteinascidin 722, edaravone, edatrexate, edelfosine, edifolone acetate, edobacomab, edoxudine, edrecolomab, edrophonium chloride, edroxyprogesteone acetate, efegatran, eflornithine, efonidipine, egualcen, elantrine, eleatonin, elemene, eletriptan, elgodipine, eliprodil, elsamitrucin, eltenae, elucaine, emalkalim, emedastine, emetine hydrochloride, emiglitate, emilium tosylate, emitefur, emoctakin, enadoline hydrochloride, enalapril, enalaprilat, enalkiren, enazadrem, encyprate, endralazine mesylate, endrysone, enflurane, englitazone, enilconazole, enisoprost, enlimomab, enloplatin, enofelast, enolicam sodium, enoxacin, enoxacin, enoxaparin sodium, enoxaparin sodium, enoximone, enpiroline phosphate, enprofylline, enpromate, entacapone, enterostatin, enviradene, enviroxime, ephedrine, epicillin, epimestrol, epinephrine, epinephryl borate, epipropidine, epirizole, epirubicin, epitetracycline hydrochloride, epithiazide, epoetin alfa, epoetin beta, epoprostenol, epoprostenol sodium, epoxymexrenone, epristeride, eprosartan, eptastigmine, eptifibatide, equilenin, equilin, erbulozole, erdosteine, ergoloid mesylates, ergonovine maleate, ergotamine tartrate, ersentilide, ersofermin, erythritol, erythrityl tetranitrate, erythromycin, esmolol hydrochloride, esomeprazole (commercially available as NEXIUM® from AstraZeneca), esorubicin hydrochloride, esproquin hydrochloride, estazolam, estradiol, estramustine, estramustine analogue, estrazinol hydrobromide, estriol, estrofurate, estrogen agonists, estrogen antagonists, estrogens, conjugated estrogens, esterified, estrone, estropipate, esuprone, etafedrine hydrochloride, etanidazole, etanterol, etarotene, etazolate hydrochloride, eterobarb, ethacizin, ethacrynate sodium, ethacrynic acid, ethambutol hydrochloride, ethamivan, ethanolamine oleate, ethehlorvynol, ether, ethinyl estradiol, ethiodized oil, ethionamide, ethonam nitrate, ethopropazine hydrochloride, ethosuximide, ethotoin, ethoxazene hydrochloride, ethybenztropine, ethyl chloride, ethyl dibunate, ethylestrenol, ethyndiol, ethynerone, ethynodiol diacetate, etibendazole, etidocaine, etidronate disodium, etidronic acid, etifenin, etintidine hydrochloride, etizolam, etodolac, etofenamate, etoformin hydrochloride, etomidate, etonogestrel, etoperidone hydrochloride, etoposide, etoprine, etoxadrol hydrochloride, etozolin, etrabamine, etretinate, etryptamine acetate, eucatropine hydrochloride, eugenol, euprocin hydrochloride, eveminomicin, exametazime, examorelin, exaprolol hydrochloride, exemestane, exetimibe (commercially available as ZETIA® from Merck), fadrozole, faeriefungin, famciclovir, famotidine (commercially available as PEPCID® from Merck), fampridine, fantof arone, fantridone hydrochloride, faropenem, fasidotril, fasudil, fazarabine, fedotozine, felbamate, felbinac, felodipine, felypressin, fenalamide, fenamole, fenbendazole, fenbufen, fencibutirol, fenclofenac, fenclonine, fenclorac, fendosal, fenestrel, fenethylline hydrochloride, fenfluramine hydrochloride, fengabine, fenimide, fenisorex, fenmetozole hydrochloride, fenmetramide, fenobam, fenoctimine sulfate, fenofibrate, fenoldopam, fenoprofen, fenoterol, fenpipalone, fenprinast hydrochloride, fenprostalene, fenquizone, fenretinide, fenspiride, fentanyl citrate, fentiazac, fenticlor, fenticonazole, fenyripol hydrochloride, fepradinol, ferpifosate sodium, ferristene, ferrixan, ferrous sulfate, ferumoxides, ferumoxsil, fetoxylate hydrochloride, fexofenadine, fezolamine fumarate, fiacitabine, fialuridine, fibrinogen I 125, filgrastim, filipin, finasteride (commercially available as PROPECIA® from Merck), flavodilol maleate, flavopiridol, flavoxate hydrochloride, flazalone, flecamide, flerobuterol, fleroxacin, flesinoxan, flestolol sulfate, fletazepam, flezelastine, flobufen, floctafenine, flomoxef, flordipine, florfenicol, florifenine, flosatidil, flosequinan, floxacillin, floxuridine, fluasterone, fluazacort, flubanilate hydrochloride, flubendazole, flucindole, flucloronide, fluconazole, flucytosine, fludalanine, fludarabine phosphate, fludazonium chloride, fludeoxyglucose F 18, fludorex, fludrocortisone acetate, flufenamic acid, flufenisal, flumazenil, flumecinol, flumequine, flumeridone, flumethasone, flumetramide, flumezapine, fluminorex, flumizole, flumoxonide, flunarizine, flunidazole, flunisolide, flunitrazepam, flunixin, fluocalcitriol, fluocinolone acetonide, fluocinonide, fluocortin butyl, fluocortolone, fluorescein, fluorodaunorunicin hydrochloride, fluorodopa F 18, fluoroformylone, fluoroquinolones, fluorometholone, fluorouracil, fluotracen hydrochloride, fluoxetine, fluoxymesterone, fluparoxan, fluperamide, fluperolone acetate, fluphenazine decanoate, fiupirtine, fiuprednisoione, fiuproquazone, fluprostenol sodium, fluquazone, fluradoline hydrochloride, flurandrenolide, flurazepam hydrochloride, flurbiprofen, fluretofen, flurithromycin, fluorocitabine, fluorof amide, fluorogestone acetate, flurothyl, fluoroxene, fluspiperone, fluspirilene, fluticasone propionate (commercially available as ADVAIR® from GlaxoSmithKline), fluticasone furoate, flutrimazole, flutroline, fluvastatin, fluvastatin sodium, fluvoxamine, fluzinamide, folic acid, follicle regulatory protein, folliculostatin, fomepizole, fonazine mesylate, fondaparinux, forasartan, forfenimex, forfenirmex, formestane, formocortal, formoterol, fosarilate, fosazepam, foscarnet sodium, fosfomycin, fosfonet sodium, fosinopril, fosinoprilat, fosphenyloin, fosquidone, fostedil, fostriecin, fotemustine, fuchsin, basic, fumoxicillin, fungimycin, furaprofen, furazolidone, furazolium chloride, furegrelate sodium, furobufen, furodazole, furosemide, fusidate sodium, fusidic acid, gabapentin, gadobenate dimeglumine, gadobenic acid, gadobutrol, gadodiamide, gadolinium texaphyrin, gadopentetate dimegiumine, gadoteric acid, gadoteridol, gadoversetamide, galantamine, galdansetron, galdansetron hydrochloride, gallamine triethiodide, gallium nitrate, gallopamil, galocitabine, gamfexine, gamolenic acid, ganciclovir, ganirelix, ganirelix acetate, gelatinase inhibitors, gemcadiol, gemcitabine (commercially available as GEMZAR® from Eli Lilly and Company), gemeprost, gemfibrozil, gentamicin sulfate, gentian violet, gepirone, gestaclone, gestodene, gestonorone caproate, gestrinone, gevotroiine hydrochloride, girisopam, glaspimod, glaucocalyxin A, glemanserin, gliamilide, glibornuride, glicetanile sodium, gliflumide, glimepiride, glipizide, gloximonam, glucagon, glutapyrone, glutathione inhibitors, glutethimide, glyburide, glycopine, glycopril, glycopyrrolate, glyhexamide, glymidine sodium, glyoctamide, glyparamide, colloidal gold Au 198, gonadoctrinins, gonadorelin, gonadotropins, goserelin, gramicidin, granisetron, grepafloxacin, griseofulvin, guaiapate, guaithylline, guanabenz, guanabenz acetate, guanadrel sulfate, guancydine, guanethidine monosulfate, guanfacine hydrochloride, guanisoquin sulfate, guanoclor sulfate, guanoctine hydrochloride, guanoxabenz, guanoxan sulfate, guanoxyfen sulfate, gusperimus trihydrochloride, halazepam, halcinonide, halichondrin B, halobetasol propionate, halof antrine, halof antrine hydrochloride, halofenate, halofuginone hydrobromide, halomon, galopemide, galoperidol, halopredone, haloprogesterone, haloprogin, halothane, halquinols, hamycin, han menopausal gonadotropins, hatomamicin, hatomarubigin A, hatomarubigin B, hatomarubigin C, hatomarubigin D, heparin sodium, hepsulfam, heregulin, hetacillin, heteronium bromide, hexachlorophene: hydrogen peroxide, hexafluorenium bromide, hexamethylene bisacetamide, hexedine, hexobendine, hexoprenaline sulfate, hexylresorcinol, hirudin, histamine phosphate, histidine, histoplasmin, histrelin, homatropine hydrobromide, hoquizil hydrochloride, human chorionic gonadotropin, hycanthone, hydralazine hydrochloride, hydralazine polistirex, hydrochlorothiazide, hydrocodone bitartrate, hydrocortisone, hydroflumethiazide, hydromorphone hydrochloride, hydroxyamphetamine hydrobromide, hydroxychloroquine sulfate, hydroxyphenamate, hydroxyprogesterone caproate, hydroxyurea, hydroxyzine hydrochloride, hymecromone, hyoscyamine, hypericin, ibafloxacin, ibandronic acid, ibogaine, ibopamine, ibudilast, ibufenac, ibuprofen, ibutilide fumarate, icatibant acetate, ichthammol, icotidine, idarubicin, idoxifene, idoxuridine, idramantone, idraparinux, iemefloxacin, iesopitron, ifetroban, ifosfamide, ilepeimide, illimaquinone, ilmofosine, ilomastat, ilonidap, iloperidone, iloprost, imafen hydrochloride, imazodan hydrochloride, imidapril, imidazenil, imidazoacridones, imidecyl iodine, imidocarb hydrochloride, imidoline hydrochloride, imidurea, imiloxan hydrochloride, imipenem, imipramine hydrochloride, imiquimod, immunostimulant peptides, impromidine hydrochloride, indacrinone, indapamide, indecamide hydrochloride, indeloxazine hydrochloride, indigotindisulfonate sodium, indinavir, indocyanine green, indolapril hydrochloride, indolidan, indometacin, indomethacin sodium, indoprofen, indoramin, indorenate hydrochloride, indoxole, indriline hydrochloride, infliximab (commercially available as REMICADE® from Janssen Biotech, Inc.), inocoterone, inogatran, inolimomab, inositol niacinate, insulin, insulin glargine (commercially available as LANTUS® from Sanofi-Aventis), interferons, interferon beta-la (commercially available as AVONEX® from BIOGEN), interleukins, intrazole, intriptyline hydrochloride, iobenguane, iobenzamic acid, iobitridol, iocarmate meglumine, iocarmic acid, iocetamic acid, iodamide, iodine, iodipamide meglumine, iodixanol, iodoamiioride, iodoantipyrine I 131, iodocholesterol I 131, iododoxorubicin, iodohippurate sodium I 131, iodopyracet I 125, iodoquinol, iodoxamate meglumine, iodoxamie acid, ioglicic acid, iofetamine hydrochloride I 123, iofratol, ioglucol, ioglucomide, ioglycamic acid, iogulamide, iohexyl, iomeprol, iomethin I 125, iopamidol, iopanoic acid, iopentol, iophendylate, ioprocemic acid, iopromide, iopronic acid, iopydol, iopydone, iopyrol, iosefamic acid, ioseric acid, iosulamide meglumine, iosumetic acid, iotasul, iotetric acid, iothalamate sodium, iothalamic acid, iotriside, iotrolan, iotroxic acid, iotyrosine I 131, ioversol, ioxagiate sodium, ioxaglate meglumine, ioxaglic acid, ioxilan, ioxotrizoic acid, ipazilide, ipenoxazone, ipidacrine, ipodate calcium, ipomeanol, 4-, ipratropium bromide, ipriflavone, iprindole, iprofenin, ipronidazole, iproplatin, iproxamine hydrochloride, ipsapirone, irbesartan, irinotecan, irloxacin, iroplact, irsogladine, irtemazole, isalsteine, isamoxole, isbogrel, isepamicin, isobengazole, isobutamben, isocarboxazid, isoconazole, isoetharine, isofloxythepin, isoflupredone acetate, isoflurane, isofluorophate, isohomohalicondrin B, isoleucine, isomazole hydrochloride, isomylamine hydrochloride, isoniazid, isopropamide iodide, isopropyl alcohol, isopropyl unoprostone, isoproterenol hydrochloride, isosorbide, isosorbide mononitrate, isotiquimide, isotretinoin, isoxepac, isoxicam, isoxsuprine hydrochloride, isradipine, itameline, itasetron, itazigrel, itopride, itraconazole, ivermectin, jasplakinolide, josamycin, kahalalide F, kalafungin, kanamycin sulfate, ketamine hydrochloride, ketanserin, ketazocine, ketazolam, kethoxal, ketipramine fumarate, ketoconazole, ketoprofen, ketorfanol, ketorolac, ketotifen fumarate, kitasamycin, labetalol hydrochloride, lacidipine, lacidipine, lactitol, lactivicin, laennec, lafutidine, lamellarin-n triacetate, lamifiban, lamivudine, lamotrigine, lanoconazole, LANOXIN® (digoxin, available from GlaxoSmithKline), lanperisone, lanreotide, lansoprazole (commercially available as PREVAID® from Takeda Pharmaceuticals, Inc.), latanoprost, lateritin, laurocapram, lauryl isoquinolinium bromide, lavoltidine succinate, lazabemide, lecimibide, leinamycin, lemildipine, leminoprazole, lenercept, leniquinsin, lenograstim, lenperone, lentinan sulfate, lepirudin, leptin, leptolstatin, lercanidipine, lergotrile, lerisetron, letimide hydrochloride, letrazuril, letrozole, leucine, leucomyzin, leuprolide acetate, leuprolide, leuprorelin, levamfetamine succinate, levamisole, levdobutamine lactobionate, levcromakalim, levetiracetam, levobetaxolol, levobunolol, levobupivacaine, levocabastine, levocarnitine, levodopa, levodropropizine, levofloxacin (commercially available as LEVAQUIN® from Jessen Pharmaceuticals, Inc.), levofuraltadone, levoleucovorin calcium, levomethadyl acetate, levomethadyl acetate hydrochloride, levomoprolol, levonantradol hydrochloride, levonordefrin, levonorgestrel, levopropoxyphene napsylate, levopropylcillin potassium, levormeloxifene, levorphanol tartrate, levosimendan, levosulpiride, levothyroxine sodium, levoxadrol hydrochloride, lexipafant, lexithromycin, liarozole, libenzapril, lidamidine hydrochloride, lidocaine, lidofenin, lidoflazine, lifarizine, lifibrate, lifibrol, linarotene, lincomycin, linear polyamine analogue, linogliride, linopirdine, linotroban, linsidomine, lintitript, lintopride, liothyronine I 125, liothyronine sodium, liotrix, lirexapride, lisinopril, lissoclinamide 7, lixazinone sulfate, lobaplatin, lobenzarit sodium, lobucavir, lodelaben, lodoxamide, lofemizole hydrochloride, lofentanil oxalate, lofepramine hydrochloride, lofexidine hydrochloride, lombricine, lomefloxacin, lomerizine, lometraline hydrochloride, lometrexol, lomitapide, lomofungin, lomoxicam, lomustine, lonapalene, lonazolac, lonidamine, loperamide hydrochloride, loracarbef, lorajmine hydrochloride, loratadine, lorazepam, lorbamate, lorcamide hydrochloride, loreclezole, lorglumide, lormetazepam, lornoxicam, lornoxicam, lortalamine, lorzafone, losartan (commercially available as COZAAR® from Merck), losigamone, losoxantrone, losulazine hydrochloride, loteprednol, lovastatin, loviride, loxapine, loxoribine, lubeluzole, lucanthone hydrochloride, lufironil, lurosetron mesylate, lurtotecan, luteinizing hormone, lutetium, lutrelin acetate, luzindole, lyapolate sodium, lycetamine, lydicamycin, lydimycin, lynestrenol, lypressin, lysine, lysofylline, lysostaphin, lytic peptides, maduramicin, mafenide, magainin 2 amide, magnesium salicylate, magnesium sulfate, magnolol, maitansine, malethamer, mallotochromene, mallotojaponin, malotilate, mangafodipir, manidipine, maniwamycin A, mannitol, mannostatin A, manumycin E, manumycin F, MAPK/ERK kinase (MEK) inhibitors, mapinastine, maprotiline, marimastat, masoprocol, maspin, massetolide, matrilysin inhibitors, maytansine, mazapertine succiniate, mazindol, mebendazole, mebeverine hydrochloride, mebrofenin, mebutamate, mecamylamine hydrochloride, mechlorethamine hydrochloride, meclocycline, meclofenamate sodium, mecloqualone, meclorisone dibutyrate, medazepam hydrochloride, medorinone, medrogestone, medroxalol, medroxyprogesterone (commercially available as DEPO-PROVERA® from Pfizer, Inc.), medrysone, meelizine hydrochloride, mefenamic acid, mefenidil, mefenorex hydrochloride, mefexamide, mefloquine hydrochloride, mefruside, megalomicin potassium phosphate, megestrol acetate, meglumine, meglutol, melengestrol acetate, melitracen hydrochloride, melphalan, memotine hydrochloride, menabitan hydrochloride, menoctone, menogaril, menotropins, meobentine sulfate, mepartricin, mepenzolate bromide, meperidine hydrochloride, mephentermine sulfate, mephenyloin, mephobarbital, mepivacaine hydrochloride, meprobamate, meptazinol hydrochloride, mequidox, meralein sodium, merbarone, mercaptopurine, mercufenol chloride, mercury, meropenem, mesalamine, meseclazone, mesoridazine, mesterolone, mestranol, mesuprine hydrochloride, metalol hydrochloride, metaproterenol polistirex, metaraminol bitartrate, metaxalone, meteneprost, meterelin, metformin, methacholine chloride, methacycline, methadone hydrochloride, methadyl acetate, methalthiazide, methamphetamine hydrochloride, methaqualone, methazolamide, methdilazine, methenamine, methenolone acetate, methetoin, methicillin sodium, methimazole, methioninase, methionine, methisazone, methixene hydrochloride, methocarbamol, methohexital sodium, methopholine, methotrexate, methotrimeprazine, methoxatone, methoxyflurane, methsuximide, methyclothiazide, methyl 10 palmoxirate, methylatropine nitrate, methylbenzethonium chloride, methyldopa, methyldopate hydrochloride, methylene blue, methylergonovine maleate, methylhistamine, R-alpha, methylinosine monophosphate, methylphenidate hydrochloride, methylprednisolone, methyltestosterone, methynodiol diacelate, methysergide, methysergide maleate, metiamide, metiapine, metioprim, metipamide, metipranolol, metizoline hydrochloride, metkephamid acetate, metoclopramide, metocurine iodide, metogest, metolazone, metopimazine, metoprine, metoproioi, metoquizine, metrifonate, metrizamide, metrizoate sodium, metronidazole, meturedepa, metyrapone, metyrosine, mexiletine hydrochloride, mexrenoate potassium, mezlocillin, mfonelic acid, mianserin hydrochloride, mibefradil, mibefradil dihydrochloride, mibolerone, michellamine B, miconazole, microcolin A, midaflur, midazolam hydrochloride, midodrine, mifepristone, mifobate, miglitol, milacemide, milameline, mildronate, milenperone, milipertine, milnacipran, milrinone, miltefosine, mimbane hydrochloride, minaprine, minaxolone, minocromil, minocycline, minoxidil, mioflazine hydrochloride, miokamycin, mipragoside, mirfentanil, mirimostim, mirincamycin hydrochloride, mirisetron maleate, mirtazapine, mismatched double stranded RNA, misonidazole, misoprostol, mitindomide, mitocarcin, mitocromin, mitogillin, mitoguazone, mitolactol, mitomalcin, mitomycin, mitonafide, mitosper, mitotane, mitoxantrone, mivacurium chloride, mivazerol, mixanpril, mixidine, mizolastine, mizoribine, moclobemide, modafinil, modaline sulfate, modecamide, moexipril, mof arotene, mofegiline hydrochloride, mofezolac, molgramostim, molinazone, molindone hydrochloride, molsidomine, mometasone, monatepil maleate, monensin, monoctanoin, montelukast sodium (commercially available as SINGULAIR® available from Merck), montirelin, mopidamol, moracizine, morantel tartrate, moricizine, morniflumate, morphine, morphine sulfate, morrhuate sodium, mosapramine, mosapride, motilide, motretinide, moxalactam disodium, moxazocine, moxiraprine, moxnidazole, moxonidine, mumps skin test antigen, mustard anticancer agent, muzolimine, mycaperoxide B, mycophenolic acid, myriaporone, nabazenil, nabilone, nabitan hydrochloride, naboctate hydrochloride, nabumetone, n-acetyldinaline, nadide, nadifloxacin, nadolol, nadroparin calcium, nafadotride, nafamostat, nafarelin, nafcillin sodium, nafenopin, nafimidone hydrochloride, naflocort, nafomine malate, nafoxidine hydrochloride, nafronyl oxalate, naftifine hydrochloride, naftopidil, naglivan, nagrestip, nalbuphine hydrochloride, nalidixate sodium, nalidixic acid, nalmefene, nalmexone hydrochloride, naloxone/pentazocine, naltrexone, namoxyrate, nandrolone phenpropionate, nantradol hydrochloride, napactadine hydrochloride, napadisilate, napamezole hydrochloride, napaviin, naphazoline hydrochloride, naphterpin, naproxen, naproxol, napsagatran, naranol hydrochloride, narasin, naratriptan, nartograstim, nasaruplase, natamycin, nateplase, naxagolide hydrochloride, nebivolol, nebramycin, nedaplatin, nedocromil, nefazodone hydrochloride, neflumozide hydrochloride, nefopam hydrochloride, nelezaprine maleate, nemazoline hydrochloride, nemorubicin, neomycin palmitate, neostigmine bromide, neridronic acid, netilmicin sulfate, neutral endopeptidase, neutramycin, nevirapine, nexeridine hydrochloride, niacin, nibroxane, nicardipine hydrochloride, nicergoline, niclosamide, nicorandil, nicotinyl alcohol, nicotine (commercially available as NICOTROL® NS from Pfizer, Inc.), nifedipine, nifirmerone, nifluridide, nifuradene, nifuraldezone, nifuratel, nifuratrone, nifurdazil, nifurimide, nifurpirinol, nifurquinazol, nifurthiazole, nilutamide, nilvadipine, nimazone, nimodipine, niperotidine, niravoline, niridazole, nisamycin, nisbuterol mesylate, nisin, nisobamate, nisoldipine, nisoxetine, nisterime acetate, nitarsone, nitazoxamide, nitecapone, nitrafudam hydrochloride, nitralamine hydrochloride, nitramisole hydrochloride, nitrazepam, nitrendipine, nitrocycline, nitrodan, nitrofurantoin, nitrofurazone, nitroglycerin, nitromersol, nitromide, nitromifene citrate, nitrous oxide, nitroxide antioxidant, nitrullyn, nivazol, nivimedone sodium, nizatidine, noberastine, nocodazole, nogalamycin, nolinium bromide, nomifensine maleate, noracymethadol hydrochloride, norbolethone, norepinephrine bitartrate, norethindrone, norethynodrel, norfloxacin, norflurane, norgestimate, norgestomet, norgestrel, nortriptyline hydrochloride, noscapine, novobiocin sodium, N-substituted benzaimides, nufenoxole, nylestriol, nystatin, 06- benzylguanine, obidoxime chloride, ocaperidone, ocfentanil hydrochloride, ocinaplon, octanoic acid, octazamide, octenidine hydrochloride, octodrine, octreotide, octriptyline phosphate, ofloxacin, oformine, okicenone, olanzapine (commercially available as ZYPREXA® from Eli Lilly and Company), oligonucleotides, olopatadine, olprinone, olsalazine, olsalazine sodium, olvanil, omeprazole, onapristone, ondansetron, ontazolast, oocyte maturation inhibitor, opipramol hydrochloride, oracin, orconazole nitrate, orgotein, orlislat, ormaplatin, ormetoprim, ornidazole, orpanoxin, orphenadrine citrate, osaterone, otenzepad, oxacillin sodium, oxagrelate, oxaliplatin, oxamarin hydrochloride, oxamisole, oxamniquine, oxandrolone, oxantel pamoate, oxaprotiline hydrochloride, oxaprozin, oxarbazole, oxatomide, oxaunomycin, oxazepam, oxcarbazepine, oxendolone, oxethazaine, oxetorone fumarate, oxfendazole, oxfenicine, oxibendazole, oxiconazole, oxidopamine, oxidronic acid, oxifungin hydrochloride, oxilorphan, oximonam, oximonam sodium, oxiperomide, oxiracetam, oxiramide, oxisuran, oxmetidine hydrochloride, oxodipine, oxogestone phenpropionate, oxolinic acid, oxprenolol hydrochloride, oxtriphylline, oxybutynin chloride, oxychlorosene, oxycodone, oxymetazoline hydrochloride, oxymetholone, oxymorphone hydrochloride, oxypertine, oxyphenbutazone, oxypurinol, oxytetracycline, oxytocin, ozagrel, ozolinone, paclitaxel, palauamine, paldimycin, palinavir, paliperidone (commercially available as INVEGA® from Janssen Pharmaceuticals, Inc.), paliperidone palmitate (commercially available as INVEGA® SUSTENNA® from Janssen Pharmaceuticals, Inc.), palmitoylrhizoxin, palmoxirate sodium, pamaqueside, pamatolol sulfate, pamicogrel, pamidronate disodium, pamidronic acid, panadiplon, panamesine, panaxytriol, pancopride, pancuronium bromide, panipenem, pannorin, panomifene, pantethine, pantoprazole, papaverine hydrochloride, parabactin, parachlorophenol, paraldehyde, paramethasone acetate, paranyline hydrochloride, parapenzolate bromide, pararosaniline pamoate, parbendazole, parconazole hydrochloride, paregoric, pareptide sulfate, pargyline hydrochloride, parnaparin sodium, paromomycin sulfate, paroxetine (commercially available as PAXIL® from GlaxoSmithKlein), parthenolide, partricin, paulomycin, pazelliptine, pazinaclone, pazoxide, pazufloxacin, pefloxacin, pegaspargase, pegorgotein, pelanserin hydrochloride, peldesine, peliomycin, pelretin, pelrinone hydrochloride, pemedolac, pemerid nitrate, pemetrexed, pemirolast, pemoline, penamecillin, penbutolol sulfate, penciclovir, penfluridol, penicillin G benzathine, penicillin G potassium, penicillin G procaine, penicillin G Sodium, penicillin V, penicillin V benzathine, penicillin V hydrabamine, penicillin V potassium, pentabamate, pentaerythritol tetranitrate, pentafuside, pentamidine, pentamorphone, bentamustine, pentapiperium methylsulfate, pentazocine, pentetic acid, pentiapine maleate, pentigetide, pentisomicin, pentizidone sodium, pentobarbital, pentomone, pentopril, pentosan, pentostatin, pentoxifylline, pentrinitrol, pentrozole, peplomycin sulfate, pepstatin, perflubron, perfof amide, perfosfamide, pergolide, perhexyline maleate, perillyl alcohol, perindopril, perindoprilat, perlapine, permethrin, perospirone, perphenazine, pethidine, phenacemide, phenaridine, phenazinomycin, phenazopyridine hydrochloride, phenbutazone sodium glycerate, phencarbamide, phencyclidine hydrochloride, phendimetrazine tartrate, phenelzine sulfate, phenindione, phenmetrazine hydrochloride, phenobarbital, phenoxybenzamine hydrochloride, phenprocoumon, phenserine, phensuccinal, phensuximide, phentermine, phentermine hydrochloride, phentolamine mesilate, phentoxifylline, phenyl aminosalicylate, phenylacetate, phenylalanine, phenylalanyl ketoconazole, phenylbutazone, phenylephrine hydrochloride, phenylpropanolamine hydrochloride, phenylpropanolamine polistirex, phenyramidol hydrochloride, phenyloin, phosphatase inhibitors, physostigmine, picenadol, picibanil, picotrin diolamine, picroliv, picumeterol, pidotimod, pifamine, pilocarpine, pilsicamide, pimagedine, pimetine hydrochloride, pimilprost, pimobendan, pimozide, pinacidil, pinadoline, pindolol, pinnenol, pinocebrin, pinoxepin hydrochloride, pioglitazone (commercially available as ACTOS® from Takeda Pharmaceuticals), pipamperone, pipazethate, pipecuronium bromide, piperacetazine, piperacillin sodium, piperamide maleate, piperazine, pipobroman, piposulfan, pipotiazine palmitate, pipoxolan hydrochloride, piprozolin, piquindone hydrochloride, piquizil hydrochloride, piracetam, pirandamine hydrochloride, pirarubicin, pirazmonam sodium, pirazolac, pirbenicillin sodium, pirbuterol acetate, pirenperone, pirenzepine hydrochloride, piretanide, pirfenidone, piridicillin sodium, piridronate sodium, piriprost, piritrexim, pirlimycin hydrochloride, pirlindole, pirmagrel, pirmenol hydrochloride, pirnabine, piroctone, pirodavir, pirodomast, pirogliride tartrate, pirolate, pirolazamide, piroxantrone hydrochloride, piroxicam, piroximone, pirprofen, pirquinozol, pirsidomine, prenylamine, pitavastatin (commercially available as LIVALOA® from Eli Lilly and Company), pituitary, posterior, pivampicillin hydrochloride, pivopril, pizotyline, placetin A, platinum compounds, platinum-triamine complex, plicamycin, plomestane, pobilukast edamine, podofilox, poisonoak extract, poldine methylsulfate, poliglusam, polignate sodium, polymyxin B sulfate, polythiazide, ponalrestat, porfimer sodium, porfiromycin, potassium chloride, potassium iodide, potassium permanganate, povidone-iodine, practolol, pralidoxime chloride, pramiracetam hydrochloride, pramoxine hydrochloride, pranolium chloride, prasugrel (commercially available as EFFIENT® from Eli Lilly and Company), pravadoline maleate, pravastatin, prazepam, prazosin, prazosin hydrochloride, prednazate, prednicarbate, prednimustine, prednisolone, prednisone, prednival, pregabalin (commercially available as LYRICA® from Pfizer, Inc.), pregnenolone succiniate, prenalterol hydrochloride, pridefine hydrochloride, prifelone, prilocalne hydrochloride, Prilosec, primaquine phosphate, primidolol, primidone, prinivil, prinomide tromethamine, prinoxodan, prizidilol hydrochloride, proadifen hydrochloride, probenecid, probicromil calcium, probucol, procainamide hydrochloride, procaine hydrochloride, procarbazine hydrochloride, procaterol hydrochloride, prochlorperazine, procinonide, proclonol, procyclidine hydrochloride, prodilidine hydrochloride, prodolic acid, prof adol hydrochloride, progabide, progesterone, proglumide, proinsulin human, proline, prolintane hydrochloride, promazine hydrochloride, promethazine hydrochloride, propafenone hydrochloride, propagermanium, propanidid, propantheline bromide, proparacaine hydrochloride, propatyl nitrate, propentofylline, propenzolate hydrochloride, propikacin, propiomazine, propionic acid, propionylcarnitine, propiram, propiram+paracetamol, propiverine, propofol, propoxycaine hydrochloride, propoxyphene hydrochloride, propranolol hydrochloride, propulsid, propyl bis- acridone, propylhexedrine, propyliodone, propylthiouracil, proquazone, prorenoate potassium, proroxan hydrochloride, proscillaridin, prostalene, prostratin, protamine sulfate, protegrin, protirelin, protosufloxacin, protriptyline hydrochloride, proxazole, proxazole citrate, proxicromil, proxorphan tartrate, prulifloxacin, pseudoephedrine hydrochloride, desloratadine/pseudoephedrine sulfate (commercially available as CLARINEX-D® from Merck), puromycin, purpurins, pyrabrom, pyrantel, pamoate, pyrazinamide, pyrazofurin, pyrazoloacridine, pyridostigmine bromide, pyrilamine maleate, pyrimethamine, pyrinoline, pyrithione sodium, pyrithione zinc, pyrovalerone hydrochloride, pyroxamine maleate, pyrrocaine, pyrroliphene hydrochloride, pyrroinitrin, pyrvinium pamoate, quadazocine mesylate, quazepam, quazinone, quazodine, quazolast, quetiapine (commercially available as SEROQUEL® available from AstraZenica), quiflapon, quinagolide, quinaldine blue, quinapril, quinaprilat, quinazosin hydrochloride, quinbolone, quinctolate, quindecamine acetate, quindonium bromide, quinelorane hydrochloride, quinestrol, quinfamide, quingestanol acetate, quingestrone, quinidine gluconate, quinielorane hydrochloride, quinine sulfate, quinpirole hydrochloride, quinterenol sulfate, quinuclium bromide, quinupristin, quipazine maleate, rabeprazole sodium, racephenicol, racepinephrine, raf antagonists, rafoxamide, ralitoline, raloxifene, raltitrexed, ramatroban, ramipril, ramoplanin, ramosetron, ranelic acid, ranimycin, ranitidine, ranolazine, rauwolfia serpentina, recainam, recainam hydrochloride, reclazepam, regavirumab, regramostim, relaxin, relomycin, remacemide hydrochloride, remifentanil hydrochloride, remiprostol, remoxipride, repirinast, repromicin, reproterol hydrochloride, reserpine, resinferatoxin, resorcinol, retelliptine demethylated, reticulon, reviparin sodium, revizinone, rhenium re 186 etidronate, rhizoxin, ribaminol, ribavirin, riboprine, ribozymes, ricasetron, ridogrel, rifabutin, rifametane, rifamexil, rifamide, rifampin, rifapentine, rifaximin, retinamide, rilopirox, riluzole, rimantadine, rimcazole hydrochloride, rimexolone, rimiterol hydrobromide, rimoprogin, riodipine, rioprostil, ripazepam, ripisartan, risedronate sodium, risedronic acid, risocaine, risotilide hydrochloride, rispenzepine, risperdal, risperidone, ritanserin, ritipenem, ritodrine, ritolukast, ritonavir, rizatriptan benzoate, rocastine hydrochloride, rocuronium bromide, rodocaine, roflurane, rogletimide, rohitukine, rokitamycin, roletamicide, rolgamidine, rolicyprine, rolipram, rolitetracycline, rolodine, romazarit, romurtide, ronidazole, ropinirole (commercially available as REQUIP® from GlaxoSmithKline), ropitoin hydrochloride, ropivacaine, ropizine, roquinimex, rosaramicin, rosoxacin, rotoxamine, rosuvastatin (commercially available as CRESTOR® available from AstraZeneca), roxaitidine, roxarsone, roxindole, roxithromycin, rubiginone Bl, ruboxyl, rufloxacin, rupatidine, rutamycin, ruzadolane, sabeluzole, safingol, safironil, saintopin, salbutamol, salcolex, salethamide maleate, salicyl alcohol, salicylamide, salicylate meglumine, salicylic acid, salmeterol, salnacediin, salsalate, sameridine, sampatrilat, sancycline, sanfetrinem, sanguinarium chloride, saperconazole, saprisartan, sapropterin, saquinavir, sarafloxacin hydrochloride, saralasin acetate, SarCNU, sarcophytol A, sargramostim, sarmoxicillin, sarpicillin, sarpogrelate, saruplase, saterinone, satigrel, satumomab pendetide, Schick test control, scopafungin, scopolamine hydrobromide, scrazaipine hydrochloride, sdi 1 mimetics, secalciferol, secobarbital, seelzone, seglitide acetate, selegiline, selegiline hydrochloride, selenium sulfide, selenomethionine se 75, selfotel, sematilide, semduramicin, semotiadil, semustine, sense oligonucleotides, sepazonium chloride, seperidol hydrochloride, seprilose, seproxetine hydrochloride, seractide acetate, sergolexole maleate, serine, sermetacin, sermorelin acetate, sertaconazole, sertindole, sertraline, setiptiline, setoperone, sevirumab, sevoflurane, sezolamide, sibopirdine, sibutramine hydrochloride, signal transduction inhibitors, siiandrone, sildenafil (commercially available as VIAGRA® from Pfizer Inc.), silipide, silteplase, silver nitrate, simendan, simtrazene, simvastatin (commercially available as ZOCOR® from Merck), sincalide, sinefungin, sinitrodil, sinnabidol, sipatrigine, sirolimus, sisomicin, sitogluside, sizofuran, sobuzoxane, sodium amylosulfate, sodium iodide I 123, sodium nitroprusside, sodium oxybate, sodium phenylacetate, sodium salicylate, solverol, solypertine tartrate, somalapor, somantadine hydrochloride, somatomedin B, somatomedin C, somatrem, somatropin, somenopor, somidobove, sonermin, sorbinil, sorivudine, sotalol, soterenol hydrochloride, sparfloxacin, sparfosate sodium, sparfosic acid, sparsomycin, sparteine sulfate, spectinomycin hydrochloride, spicamycin D, spiperone, spiradoline mesylate, spiramycin, spirapril hydrochloride, spiraprilat, spirogermanium hydrochloride, spiromustine, spironolactone, spiroplatin, spiroxasone, splenopentin, spongistatin 1, sprodiamide, squalamine, stallimycin hydrochloride, stannous pyrophosphate, stannous sulfur colloid, stanozolol, statolon, staurosporine, stavudine, steffimycin, stenbolone acetate, stepronin, stilbazium iodide, stilonium iodide, stipiamide, stiripentol, stobadine, streptokinase, streptomycin sulfate, streptonicozid, streptonigrin, streptozocin, stromelysin inhibitors, strontium chloride Sr 89, succibun, succimer, succinylcholine chloride, sucralfate, sucrosof ate potassium, sudoxicam, sufentanil, sufotidine, sulazepam, sulbactam pivoxil, sulconazole nitrate, sulfabenz, sulfabenzamide, sulfacetamide, sulfacytine, sulfadiazine, sulfadoxine, sulfalene, sulfamerazine, sulfameter, sulfamethazine, sulfamethizole, sulfamethoxazole, sulfamonomethoxine, sulfamoxole, sulfanilate zinc, sulfanitran, sulfasalazine, sulfasomizole, sulfazamet, sulfinalol hydrochloride, sulfinosine, sulfinpyrazone, sulfisoxazole, sulfomyxin, sulfonterol hydrochloride, sulfoxamine, sulinldac, sulmarin, sulnidazole, suloctidil, sulofenur, sulopenem, suloxifen oxalate, sulpiride, sulprostone, sultamicillin, sulthiame, sultopride, sulukast, sumarotene, sumatriptan, suncillin sodium, suproclone, suprofen, suradista, suramin, surfomer, suricamide maleate, suritozole, suronacrine maleate, suxemerid sulfate, swainsonine, symakalim, symclosene, symetine hydrochloride, synthetic glycosaminoglycans, tadalafil (commercially available as CIALIS® and ACIRCA® from from Eli Lilly and Company), taciamine hydrochloride, tacrine hydrochloride, tacrolimus, talampicillin hydrochloride, taleranol, talisomycin, tallimustine, talmetacin, talniflumate, talopram hydrochloride, talosalate, tametraline hydrochloride, tamoxifen (commercially available as NOLVADEX® from AstraZeneca), tampramine fumarate, tamsulosin hydrochloride, tandamine hydrochloride, tandospirone, tapgen, taprostene, tasosartan, tauromustine, taxane, taxoid, tazadolene succinate, tazanolast, tazarotene, tazifylline hydrochloride, tazobactam, tazofelone, tazolol hydrochloride, tebufelone, tebuquine, technetium Tc 99 m bicisate, teclozan, tecogalan sodium, teecleukin, teflurane, tegafur, tegretol, teicoplanin, telenzepine, tellurapyrylium, telmesteine, telmisartan, telomerase inhibitors, teloxantrone hydrochloride, teludipine hydrochloride, temafloxacin hydrochloride, tematropium methyl sulfate, temazepam, temelastine, temocapril, temocillin, temoporfin, temozolomide, tenofovir, tenidap, teniposide, tenosal, tenoxicam, tepirindole, tepoxalin, teprotide, terazosin, terbinafine, terbutaline sulfate (commercially available as BRICANYL® from AstraZeneca), terconazole, terfenadine, terflavoxate, terguride, teriparatide acetate, terlakiren, terlipressin, terodiline, teroxalene hydrochloride, teroxirone, tertatolol, terutroban, tesicam, tesimide, testolactone, testosterone, tetracaine, tetrachlorodecaoxide, tetracycline, tetrahydrozoline hydrochloride, tetramisole hydrochloride, tetrazolast meglumine, tetrazomine, tetrofosmin, tetroquinone, tetroxoprim, tetrydamine, thaliblastine, thalidomide, theofibrate, theophylline, thiabendazole, thiamiprine, thiamphenicol, thiamylal, thiazesim hydrochloride, thiazinamium chloride, thiazolidinedione, thiethylperazine, thimerfonate sodium, thimerosal, thiocoraline, thiofedrine, thioguanine, thiomarinol, thiopental sodium, thioperamide, thioridazine, thiotepa, thiothixene, thiphenamil hydrochloride, thiphencillin potassium, thiram, thozalinone, threonine, thrombin, thrombopoietin, thrombopoietin mimetic, thromboxane synthase inhibitors, thromboxane receptor, antagonists, thymalfasin, thymopoietin receptor agonist, thymotrinan, thyromedan hydrochloride, thyroxine 1 125, thyroxine 1 131, tiacrilast, tiacrilast sodium, tiagabine, tiamenidine, tianeptine, tiapafant, tiapamil hydrochloride, tiaramide hydrochloride, tiazofurin, tibenelast sodium, tibolone, tibric acid, ticabesone propionate, ticarbodine, ticarcillin cresyl sodium, ticagrelor, ticlopidine, ticlatone, ticlopidine, ticrynafen, tienoxolol, tifurac sodium, tigemonam dicholine, tigestol, tiletamine hydrochloride, tilidine hydrochloride, tilisolol, tilnoprofen arbamel, tilorone hydrochloride, tiludronate disodium, tiludronic acid, timefurone, timobesone acetate, timolol, tin ethyl etiopurpurin, tinabinol, timidazole, tinzaparin sodium, tioconazole, tiodazosin, tiodonium chloride, tioperidone hydrochloride, tiopinac, tiospirone hydrochloride, tiotidine, tiotropium bromide, tioxidazole, tipentosin hydrochloride, tipredane, tiprenolol hydrochloride, tiprinast meglumine, tipropidil hydrochloride, tiqueside, tiquinamide hydrochloride, tirandalydigin, tirapazamine, tirilazad, tirofiban, tiropramide, titanocene dichloride, tixanox, tixocortol pivalate, tizanidine hydrochloride, tobramycin, tocamide, tocamphyl, tofenacin hydrochloride, tolamolol, tolazamide, tolazoline hydrochloride, tolbutamide, tolcapone, tolciclate, tolfamide, tolgabide, lamotrigine, tolimidone, tolindate, tolmetin, tolnaftate, tolpovidone 1 131, tolpyrramide, tolrestat, tomelukast, tomoxetine hydrochloride, tonazocine mesylate, topiramate, topotecan, topotecan hydrochloride, topsentin, topterone, toquizine, torasemide, toremifene, torsemide, tosifen, tosufloxacin, totipotent stem cell factor, tracazolate, trafermin, tralonide, tramadol hydrochloride, tramazoline hydrochloride, trandolapril, tranexamic acid, tranilast, transcamide, translation inhibitors, trastuzumab (commercially available as HERCEPTIN® from Genentech), traxanox, trazodone hydrochloride, trazodone-hcl, trebenzomine hydrochloride, trefentanil hydrochloride, treloxinate, trepipam maleate, trestolone acetate, tretinoin, triacetin, triacetyluridine, triafungin, triamcinolone, triampyzine sulfate, triamterene, triazolam, tribenoside, tricaprilin, tricetamide, trichlormethiazide, trichohyalin, triciribine, tricitrates, triclofenol piperazine, triclofos sodium, triclonide, trientine, trifenagrel, triflavin, triflocin, triflubazam, triflumidate, trifluoperazine hydrochloride, trifluperidol, triflupromazine, triflupromazine hydrochloride, trifluridine, trihexyphenidyl hydrochloride, trilostane, trimazosin hydrochloride, trimegestone, trimeprazine tartrate, trimethadione, trimethaphan camsylate, trimethobenzamide hydrochloride, trimethoprim, trimetozine, trimetrexate, trimipramine, trimoprostil, trimoxamine hydrochloride, triolein 1 125, triolein 1 131, trioxifene mesylate, tripamide, tripelennamine hydrochloride, triprolidine hydrochloride, triptorelin, trisulfapyrimidines, troclosene potassium, troglitazone, trolamine, troleandomycin, trombodipine, trometamol, tropanserin hydrochloride, tropicamide, tropine ester, tropisetron, trospectomycin, trovafloxacin, trovirdine, tryptophan, tuberculin, tubocurarine chloride, tubulozole hydrochloride, tucarcsol, tulobuterol, turosteride, tybamate, tylogenin, tyropanoate sodium, tyrosine, tyrothricin, tyrphostins, ubenimex, uldazepam, undecylenic acid, uracil mustard, urapidil, urea, uredepa, uridine triphosphate, urofollitropin, urokinase, ursodiol, valaciclovir, valine, valnoctamide, valproate sodium, valproic acid, valsartan (commercially available as DIOVAN® from Novartis Pharmaceuticals), vamicamide, vanadeine, vancomycin, vaminolol, vapiprost hydrochloride, vapreotide, vardenafil (commercially available as LEVITRA® from GlaxoSmithKline), variolin B, vasopressin, vecuronium bromide, velaresol, velnacrine maleate, venlafaxine, veradoline hydrochloride, veramine, verapamil hydrochloride, verdins, verilopam hydrochloride, verlukast, verofylline, veroxan, verteporfin, vesnarinone, vexibinol, vidarabine, vigabatrin, viloxazine hydrochloride, vinblastine sulfate, vinburnine citrate, vincofos, vinconate, vincristine sulfate, vindesine, vindesine sulfate, vinepidine sulfate, vinglycinate sulfate, vinleurosine sulfate, vinorelbine, vinpocetine, vintoperol, vinxaltine, vinzolidine sulfate, viprostol, virginiamycin, viridofulvin, viroxime, vitaxin, volazocine, voriconazole, vorozole, voxergolide, warfarin sodium, xamoterol, xanomeline, xanoxate sodium, xanthinol niacinate, xemilofiban, xenalipin, xenbucin, xilobam, ximoprofen, xipamide, xorphanol mesylate, xylamidine tosylate, xylazine hydrochloride, xylometazoline hydrochloride, xylose, yangambin, zabicipril, zacopride, zafirlukast, zalcitabine, zaleplon, zalospirone, zaltidine hydrochloride, zaltoprofen, zanamivir, zankiren, zanoterone, zantac, za rirlukast, zatebrad ine, zatosetron, zatosetron maleate, zenarestat, zenazoci ne mesylate, zeni plati n, zera nol , zidometaci n, zidovud ine, zifrosi lone, zila ntel, zilascorb, zileuton, zimeld ine hyd roch loride, zinc undecylenate, zindotri ne, zinoconazole hyd rochloride, zinostati n, zinterol hyd roch loride, zinvi roxi me, ziprasidone, zobolt, zofenopri l ca lci um, zofenopri lat, zolam ine hydrochloride, zolazepa m hyd rochloride, zoled ron ie acid, zolerti ne hyd rochloride, zol mitri pta n, Zol pidem, zomepi rac sodi um, zometapi ne, zoniclezole hyd rochloride, zon isa mide, zopiclone, zopol restat, zorba myci in, zoru bici n hyd rochloride, zotepi ne, zucapsaici n, JTT-501 ( PN U- 1827 16) (reg litaza r), AR-H 039 122, MCC- 555 (netog litazone), AR- H049020 (tesag litazar), CS-0 11 (CI- 1037), GW-409 544 x , KRP-297, RG- 12525, B - 15.2054, CLX-0940, CLX-092 1, DRF-2 189, GW- 1929, GW-9820, LR-90, LY-510929, NIP-22 1, NIP-223, JTP-20993, LY 293 11 Na, FK 614, BMS 298585, R 483, TAK 559, DRF 2725 (ragag litaza r), L-686398, L- 168049, L-80 5645, L-054852, demethyl asteriq uinone Bl (L-78328 1), L- 363 586, KRP-297, P32/98, CRE- 16336, E L- 1625, pha rmaceutical ly acceptable sa lts thereof {e.g., Zn, Fe, Mg, K, Na, F, CI, Br, I, acetate, diacetate, nitrate, nitrite, sulfate, sulfite, phosphate, and phosphite sa lts), pha rmaceutical ly accepta ble forms thereof with acid associates (e. g. HCI), and any com bination thereof. [0096] Suita ble anti biotics for use in conj unction with the molded polyethylene components of the present invention may include, but are not limited to, to β - lacta m anti biotics (e.g., benzathi ne penicil lin, benzyl pen ici llin

(penici llin G), phenoxymethyl penici llin (penicil lin V), proca ine pen ici llin, methici llin, oxaci llin, nafci llin, cloxacil lin, dicloxaci llin, flucloxaci llin, temoci llin, amoxici llin, ampici llin, co-a moxiclav (amoxici llin+clavu la nic acid), azloci llin, ca rbenici llin, tica rci llin, mezloci llin, piperaci llin, cepha lospori n, cepha lexi n, cepha lothi n, cefazol in, cefaclor, cefu roxi me, cefamandole, cefoteta n, cefoxiti n, ceftriaxone, cefotaxi me, cefpodoxi me, cefixi me, ceftazid ime, cefepi me, cefpi rome, ca rba penem, imipenem (with cilastati n), meropenem, erta penem, faropenem, dori penem, aztreona m (com mercia lly ava ilable as AZACTAM® from Bristol- Myers Sq uibb), tigemona m, noca rdici n A, tabtoxin ine- - lacta m, clavu lan ic acid, tazobacta m, and sulbacta m) ; aminoglycoside anti biotics (e.g., aminoglycoside, amikaci n, apra myci n, arbekaci n, astrom ici n, beka namyci n, ca preomyci n, dibekaci n, dihyd rostreptomyci n, elsa mitruci n, G4 18, genta micin, hyg romyci n B, isepa mici n, kanamyci n, kasuga myci n, micronom ici n, neomyci n, neti lmici n, paromomycin sulfate, ribosta mycin, sisomici n, streptod uoci n, streptomyci n, tobra myci n, verda mici n; sulfona mides such as sulfamethoxazole, sulfisom idi ne (also known as sulfaisod imid ine), sulfaceta mide, sulfadoxi ne, dichlorphena mide (DCP), and dorzola mide) ; quinolone anti biotics (e.g., cinobac, flu meq uine, nalidixic acid, oxol inic acid, piromid ic acid, pipem idic acid, rosoxaci n, ciprofloxaci n, enoxaci n, fleroxacin, lomefloxaci n, nad ifloxaci n, norfloxacin, ofloxaci n, pefloxaci n, rufloxaci n, ba lofloxaci n, grepafloxaci n, levofloxaci n, pazufloxaci n, spa rfloxaci n, temafloxaci n, tosufloxacin, clinafloxaci n, gatifloxaci n, gem ifloxaci n, moxifloxaci n, sitafloxacin, trovafloxaci n, pru lifloxaci n, garenoxaci n, and delafloxaci n) ; oxazol idone anti biotics (e.g., linezol id, torezol id, eperezol id, posizol id, and radezol id), and any com bination thereof. [0097] Suitable antifu nga ls for use in conju nction with the molded polyethylene com ponents of the present invention may incl ude, but are not limited to, polyene antifu nga ls (e.g., nata myci n, rimocidi n, filipin, nystati n, amphoterici n B, ca nd ici n, and hamyci n; imidazole antifu ngals such as miconazole (com mercial ly ava ila ble as ICATIN ® from WellSpri ng Pha rmaceutica l Corporation), ketoconazole (com mercial ly avai la ble as NIZORAL® from McNei l consu mer Hea lthca re), clotri mazole (com mercia lly ava ilable as LOTRAMI N® and LOTRAMI N AF® avai la ble from Merck and CAN ESTEN ® ava ila ble from Bayer), econazole, omoconazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole (com mercia lly avai la ble as ERTACZO® from OrthoDematolog ics), sulconazole, and tioconazole; triazole antifu ngals such as fluconazole, itraconazole, isavuconazole, ravuconazole, posaconazole, voriconazole, terconazole, and albaconazole), thiazole antifu nga ls (e.g., abafu ngin), allylam ine antifu nga ls (e.g., terbi nafi ne (com mercia lly ava ila ble as LAM ISI L® from Novartis Consu mer Hea lth, I nc. ), naftifi ne (com mercia lly avai la ble as NAFTIN ® ava ila ble from Merz Pharmaceutica ls), and butenafi ne (com mercia lly avai la ble as LOTRAMI N ULTRA® from Merck), ech inoca nd in antifu ngals (e.g., anid ulafu ngin, caspofu ngi n, and micafu ng in), polygod ial, benzoic acid, ciclopi rox, tol naftate (e.g., commercia lly ava ilable as TINACTIN ® from MDS Consu mer Ca re, Inc. ), undecylenic acid, flucytosi ne, 5-fl uorocytosi ne, griseofu lvi n, haloprog in, and any com bination thereof. [0098] Suita ble active biolog icals for use in conj unction with the molded polyethylene com ponents of the present invention may incl ude, but are not limited to, hormones (synthetic or natu ral and patient derived or otherwise), DNAs (synthetic or natu ral and patient derived or otherwise), RNAs (synthetic or natu ral and patient derived or otherwise), siRNAs (synthetic or natu ral and patient derived or otherwise), protei ns and peptides (e.g., albumin, atria l natri uretic factor, reni n, superoxide dismutase, α- 1-antitrypsi n, lung surfacta nt protei ns, bacitraci n, bestati n, cydospori ne, delta sleep-i nd uci ng peptide (DSIP), endorphi ns, glucagon, gramicidi n, mela nocyte inhibiti ng factors, neu rotensi n, oxytoci n, somostati n, terprotide, seru m thym ide factor, thymosi n, DDAVP, dermorphi n, Met-enkepha lin, peptidog lycan, satieti n, thymopenti n, fibri n deg radation prod uct, des-enkephal in-a-endorphi n, gonadotropi n releasi ng hormone, leu prol ide, a-M SH, and metkepha mid), enzymes, nucleotides, olig ionucleotides, anti bod ies, monoclonal anti bodies, growth factors (e.g., epidermal growth factor (EGF), fibroblast growth factors, basic fibroblast growth factor (bFG F), nerve growth factor (NGF), bone derived growth factor (BDG F), tra nsform ing growth factors, tra nsformi ng growth factor- β ΐ (TG F- β Ι ), and human growth hormone (hGH)), viral surface antigens (e.g., adenoviruses, epstei n- barr virus, hepatitis A virus, hepatitis B virus, herpes viruses, HIV- 1, HIV-2, HTLV-III, infl uenza viruses, Ja panese encepha litis virus, measles virus, pa pilloma viruses, paramyxovi ruses, pol io virus, rabies virus, rubel la virus, vacci nia (smal lpox) viruses, and yel low fever virus), bacteria l surface antigens (e.g., bordetel la pertussis, hel icobacter pylorn, Clostrid ium teta ni, corynebacteri um diphtheria, escherichia col i, haemoph ilus infl uenza, klebsiel la species, legionel la pneu mophi la, mycobacteri um bovis, mycobacteri um leprae, mycrobacteri um t ubercu losis, neisseria gonorrhoeae, neisseria men ing itid is, proteus species, pseudomonas aerugi nosa, sal monel la species, shigel la species, sta phylococcus aureus, streptococcus pyogenes, vibrio cholera, and yersi nia pestis), parasite surface antigens (e.g., Plasmod ium vivax - mala ria, Plasmodi um falci pa rum - mala ria, Plasmod ium ovale - mala ria, Plasmod ium mala riae - mala ria, leishma nia tropica - leishman iasis, leishmania donova ni, leish man iasis, leishman ia bra nzi liensis - leishma niasis, trypa nosoma rhodescense - sleepi ng sickness, trypa nosoma gambiense - sleepi ng sickness, trypa nosoma cruzi - Chagas' disease, sch istosoma manson i - schistosom iasis, schistosomoma haematobi um - schistomiasis, schistosoma j aponicu m - shichtom iasis, trich inel la spi ral is - trichi nosis, strong lyloides duodena le - hookworm, ancyclostoma duodenale - hookworm, necator america nus - hookworm, wucheria bancrofti - fila riasis, brug ia malaya - fila riasis, loa loa - fila riasis, dipeta lonema persta ris - filariasis, dracu ncu la med inensis - filariasis, and onchocerca volvu lus - fila riasis), immunogobu lins (e.g., IgG, IgA, Ig , anti rabies immunog lobu lin, and antivacci nia immunoglobu lin), and any com bination thereof. [0099] Suitable antitoxi ns for use in conj unction with the molded polyethylene com ponents of the present invention may incl ude, but are not limited to, botu linum antitoxi n, diphtheria antitoxi n, gas gang rene antitoxi n, teta nus antitoxi n, and any com bination thereof. [0100] Suita ble antigens for use in conj unction with the molded polyethylene com ponents of the present invention may incl ude, but are not limited to, hormones and growth factors (e.g., fol licle sti mulati ng hormone, prolacti n, ang iogeni n, epidermal growth factor, calciton in, erythropoieti n, thyrotropic releasi ng hormone, insu lin, growth hormones, insu lin-l ike growth factors 1 and 2, skeleta l growth factor, human chorionic gonadotropi n, lutei nizi ng hormone, nerve growth factor, adrenocorticotropic hormone (ACTH ), lutei nizi ng hormone releasi ng hormone (LH RH), parathyroid hormone (PTH), thyrotropi n releasi ng hormone (TRH), vasopressin, cholecystoki nin, and corticotropi n releasi ng hormone), cytoki nes (e.g., interferons, interleu kins, colony sti mulati ng factors, and t umor necrosis factors : fibri nolytic enzymes, such as uroki nase, kid ney plasm inogen activator), clotti ng factors (e.g., Protei n C, Factor VIII, Factor IX, Factor VII and Antithrom bin III), and any com bination thereof. [0101] Suita ble nutritiona l supplements for use in conj unction with the antigents present invention may incl ude, but are not limited to, vita mins, minera ls, herbs, bota nicals, amino acids, steroids, and the like. [0102] Suita ble nutraceutica ls for use in conj unction with the molded polyethylene com ponents present invention may incl ude, but are not lim ited to, dietary supplements, bota nica ls, functiona l foods and extracts thereof, med ici nal foods and extracts thereof, vita mins, minera ls, co-enzyme Q, ca rniti ne, multi- mineral form ulas, gingseng, ging ko biloba, saw palmetto, other plant- based supplements, probiotics, omega-3, ca nola and other oils, pla nt stands, natu ral sweeteners, mush room extracts, chocolate, chocolate extracts, grape extracts, berry extracts, super food extracts, quillaja mol ina extracts, pla nt extracts, yucca schid igera extract, bra n, ala nine, beta-ca rotene, carotenoids, arginin, vitamin A, asparagine, vitamin B-complex, aspartate, vitamin C, leucine, isoleucine, valine, vitamin D, citrulline, vitamin E, cysteine, vitamin K, glutamine, minerals, micro-nutrients, glutamic acid, calcium, glycine, chromium, histidine, copper, lysine, iodine, methionine, iron, ornithine, magnesium, phenylalanine, potassium, proline, selenium, serine, zinc, taurine, threonine, alpha lipoic acid, tryptophan, green tea extracts, tyrosine, essential fatty acids (EFA), whey protein, flax seed oil, and any combination thereof. [0103] A typical dosage of APIs may range from about 0.001 mg/kg to about 1000 mg/kg, preferably from about 0.01 mg/kg to about 100 mg/kg, and more preferably from about 0 .10 mg/kg t o about 20 mg/kg, relative to weight of the patient. I n some embodiments, an API may be used alone or in combination with another API. One skilled in the art should understand the dose and/or combination of agents should be chosen so as to minimize adverse interactions. [0104] Embodiments disclosed herein include: A : a biomedical device that comprises a molded polyethylene component that comprises a polyethylene composition that comprises polyethylene having a melt flow index of about 3.5 g/10 min or greater as measured by ASTM D1238 at 190°C/21.5 kg weight and having an ash content of about 500 ppm or less; B: a biomedical device that comprises a conduit that comprises at least one wall defining an internal volume, the at least one wall comprising: polyethylene having a melt flow index of about 3.5 g/10 min or greater as measured by ASTM D1238 at 190°C/21.5 kg weight and having an ash content of about 500 ppm or less; C: a method that comprises providing a polyethylene composition melt that comprises polyethylene having a melt flow index of about 3.5 g/10 min or greater as measured by ASTM D1238 at 190°C/21.5 kg weight and having an ash content of about 500 ppm or less; and extruding the polyethylene composition melt t o form a molded polyethylene component of a biomedical device; D : a method that comprises providing a polyethylene composition melt that comprises polyethylene having a melt flow index of about 3.5 g/10 min or greater as measured by ASTM D1238 at 190°C/21.5 kg weight and having an ash content of about 500 ppm or less; and injection molding the polyethylene composition melt t o form a molded polyethylene component of a biomedical device; E: a method that comprises providing a component of a biomedical device; and substantially encasing the component in polyethylene having a melt flow index of about 3.5 g/10 min or greater as measured by ASTM D1238 at 190°C/21.5 kg weight and having an ash content of about 500 ppm or less; F: a method that comprises providing a sheet comprising a polyethylene composition that comprises polyethylene having a melt flow index of about 3.5 g/10 min or greater as measured by ASTM D1238 at 190°C/21.5 kg weight and having an ash content of about 500 ppm or less; and thermoforming the sheet into a molded polyethylene component of a biomedical device; and G : a method that comprises providing a sheet comprising a polyethylene composition that comprises polyethylene having a melt flow index of about 3.5 g/10 min or greater as measured by ASTM D1238 at 190°C/21.5 kg weight and having an ash content of about 500 ppm or less; and shrink wrapping the sheet onto a portion of a biomedical device or component thereof; and H : a method that comprises polymerizing at least one olefin in the presence of a catalyst so as to form polyethylene having a melt flow index of about 3.5 g/10 min or greater as measured by ASTM D1238 at 190°C/21.5 kg weight, the at least one olefin being selected from the group consisting of ethylene, propylene, and/or butylene, and any combination thereof; and treating the polyethylene to yield a treated polyethylene having an ash content of about 500 ppm or less. [0105] Each of embodiments A-G may independently have one or more of the following additional elements in any combination: Element 1 : the polyethylene having a specific gravity of about 0.93 g/cm3 to about 0.97 g/cm 3; Element 2 : the polyethylene having an average molecular weight of about 30,000 g/mol to about 2,500,000 g/mol; Element 3 : the polyethylene comprising a copolymer of ethylene and at least one monomer selected from the group consisting of propylene, butylene, and any combination thereof; Element 4 : the polyethylene being crosslinked; Element 5 : the polyethylene composition being foamed; Element 6 : the molded polyethylene component is nonload- bearing; Element 7 : the biomedical device being nonload-bearing or load- bearing; Element 8 : the polyethylene composition further comprising an active pharmaceutical ingredient; Element 9 : the polyethylene composition further comprising an imaging agent; Element 10: the polyethylene composition further comprising at least one selected from the group consisting of a second polymer, a plasticizer, a compatibilizer, an antioxidant, a reinforcing filler, a pigment, a dye, a radioopaque filler, a lubricant, a processing aid, a light stabilizer, a neutralizer, an antiblock, and any combination thereof; Element 11: the molded polyethylene component (or the like, e.g., a sheet) further comprising a reinforcing structure, wherein the polyethylene composition is disposed on at least a portion of a surface of the reinforcing structure; Element 12: the biomedical device further comprising other components, and wherein the molded polyethylene component substantially encases the other components; Element 13: the biomedical device being at least one selected from the group consisting of a chip, an RFID tag, tubing, a pump, a feeding tube, a catheter, a vascular catheter, a prosthetic, an inflatable balloon, a stent, a heart valve, a neurostimulator, a cochlear implant, a cranio-maxillofacial implant, synthetic cartilage, a stomach ring, a surgical instrument, a blood vessel clamp, an aneurysm clip, a spinal plug for use in conjunction with a joint fusion system, a base-plate stem cap for an artificial joint, a muscle implant, a nasopharyngeal implant, and a laryngeal implant, a drug delivery device, a transdermal patch, a subdermal implant, an oromucosal insert, an intrauterine device, an intravaginal ring, and a dental fiber; Element 14: the biomedical device being in a kit with a set of instructions; Element 15: implanting the biomedical device in a patient; and Element 16: treating a patient with the biomedical device. Embodiment H may have one or more of the following additional elements in any combination: Element 17: the treated polyethylene having a specific gravity of about 0.93 g/cm3 to about 0.97 g/cm 3; Element 18: the treated polyethylene having an average molecular weight of about 30,000 g/mol to about 2,500,000 g/mol; Element 19: treating involves exposing the polyethylene concurrently or in series to at least one selected from the group consisting of steam, an inert solvent the catalyst is at least partially soluble in, an acid, acetone, water, a halogenated solvent, and any combination thereof; Element 20: treating involves increased temperature and/or decreased pressure; and Element 21: forming a molded polyethylene component of a biomedical device from the treated polyethylene. [0106] By way of non-limiting example, exemplary combinations independently applicable to embodiments A-G include: at least two of Elements 1-6 in combination; Element 8 in combination with at least one of Elements 1-6; Element 9 in combination with at least one of Elements 1-6; Element 10 in combination with at least one of Elements 1-6; Element 13 in combination with at least one of Elements 1-6; Elements 8 and 13 in combination with at least one of Elements 1-6; Elements 9 and 13 in combination with at least one of Elements 1-6; Element 1 in combination with Element 4; Elements 10 and 13 in combination with at least one of Elements 1-6; Element 13 in combination with at least two of Elements 8-10 and at least one of Elements 1-6; Element 14 in combination with the foregoing any of the combinations; Element 15 in combination with the foregoing any of the combinations; Element 16 in combination with the foregoing any of the combinations; and so on. [0107] Therefore, the present invention is well adapted to attain the ends and advantages mentioned as well as those that are inherent therein. The particular embodiments disclosed above are illustrative only, as the present invention may be modified and practiced in different but equivalent manners apparent to those skilled in the art having the benefit of the teachings herein. Furthermore, no limitations are intended to the details of construction or design herein shown, other than as described in the claims below. It is therefore evident that the particular illustrative embodiments disclosed above may be altered, combined, or modified and all such variations are considered within the scope and spirit of the present invention. The invention illustratively disclosed herein suitably may be practiced in the absence of any element that is not specifically disclosed herein and/or any optional element disclosed herein. While compositions and methods are described in terms of "comprising," "containing," or "including" various components or steps, the compositions and methods can also "consist essentially of" or "consist of" the various components and steps. All numbers and ranges disclosed above may vary by some amount. Whenever a numerical range with a lower limit and an upper limit is disclosed, any number and any included range falling within the range is specifically disclosed. I n particular, every range of values (of the form, "from about a to about b," or, equivalently, "from approximately a to b," or, equivalently, "from approximately a-b") disclosed herein is to be understood to set forth every number and range encompassed within the broader range of values. Also, the terms in the claims have their plain, ordinary meaning unless otherwise explicitly and clearly defined by the patentee. Moreover, the indefinite articles "a" or "an," as used in the claims, are defined herein to mean one or more than one of the element that it introduces. If there is any conflict in the usages of a word or term in this specification and one or more patent or other documents that may be incorporated herein by reference, the definitions that are consistent with this specification should be adopted. CLAIMS The invention claimed is: 1. A biomedical device comprising: a molded polyethylene component that comprises a polyethylene composition that comprises polyethylene having a melt flow index of about 3.5 g/10 min or greater as measured by ASTM D1238 at 190°C/21.5 kg weight and having an ash content of about 500 ppm or less. 2 . The biomedical device of claim 1, wherein the polyethylene has a specific gravity of about 0.93 g/cm 3 to about 0.97 g/cm 3. 3 . The biomedical device of one of the preceeding claims, wherein the polyethylene has an average molecular weight of about 30,000 g/mol to about 2,500,000 g/mol. 4 . The biomedical device of one of the preceeding claims, wherein the polyethylene comprises a copolymer of ethylene and at least one monomer selected from the group consisting of propylene, butylene, and any combination thereof. 5 . The biomedical device of one of the preceeding claims, wherein the polyethylene is crosslinked. 6 . The biomedical devices of one of the preceeding claims, wherein the polyethylene composition is foamed. 7 . The biomedical device of one of the preceeding claims, wherein the molded polyethylene component is nonload-bearing. 8 . The biomedical device of one of the preceeding claims, wherein the biomedical device is nonload-bearing. 9 . The biomedical device of one of the preceeding claims, wherein the biomedical device is load-bearing. 10. The biomedical device of one of the preceeding claims, wherein the molded polyethylene component has been formed into a desired shape from a polyethylene composition melt that comprises the polyethylene. 11. The biomedical device of one of the preceeding claims, wherein the polyethylene composition further comprises an active pharmaceutical ingredient. 12. The biomedical device of one of the preceeding claims, wherein the polyethylene composition further comprises an imaging agent. 13. The biomedical device of one of the preceeding claims, wherein the polyethylene composition further comprises at least one selected from the group consisting of a second polymer, a plasticizer, a compatibilizer, an antioxidant, a reinforcing filler, a pigment, a dye, a radioopaque filler, a lubricant, a processing aid, a light stabilizer, a neutralizer, an antiblock, and any combination thereof. 14. The biomedical device of one of the preceeding claims, wherein the molded polyethylene component further comprises a reinforcing structure, wherein the polyethylene composition is disposed on at least a portion of a surface of the reinforcing structure. 15. The biomedical device of claim 14, wherein the reinforcing structure comprises at least one selected from the group consisting of ultra high molecular weight polyethylene, a metal, a metal alloy, a ceramic, and any combination thereof. 16. The biomedical device of one of the preceeding claims, wherein the biomedical device further comprises other components, and wherein the molded polyethylene component substantially encases the other components. 17. The biomedical device of one of the preceeding claims being at least one selected from the group consisting of a chip, an RFID tag, tubing, a pump, a feeding tube, a catheter, a vascular catheter, a prosthetic, an inflatable balloon, a stent, a heart valve, a neurostimulator, a cochlear implant, a cranio- maxillofacial implant, synthetic cartilage, a stomach ring, a surgical instrument, a blood vessel clamp, an aneurysm clip, a spinal plug for use in conjunction with a joint fusion system, a base-plate stem cap for an artificial joint, a muscle implant, a nasopharyngeal implant, a laryngeal implant, a drug delivery device, a transdermal patch, a subdermal implant, an oromucosal insert, an intrauterine device, an intravaginal ring, and a dental fiber. 18. A kit comprising the biomedical device of one of the preceeding claims and a set of instructions. 19. A method comprising: implanting the biomedical device of one of the preceeding claims into a patient. 20. A method comprising: treating a patient with the biomedical device of one of the preceeding claims. 21. A biomedical device comprising: a conduit that comprise at least one wall defining an internal volume, the at least one wall comprising: polyethylene having a melt flow index of about 3.5 g/10 min or greater as measured by ASTM D1238 at 190°C/21.5 kg weight and having an ash content of about 500 ppm or less. 22. The biomedical device of claim 21, wherein the polyethylene has a specific gravity of about 0.93 g/cm 3 to about 0.97 g/cm 3. 23. The biomedical device of one of claims 21-22, wherein the polyethylene has an average molecular weight of about 30,000 g/mol to about 2,500,000 g/mol. 24. The biomedical device of one of claims 21-23, wherein the polyethylene is crosslinked. 25. The biomedical device of one of claims 21-24, wherein the polyethylene comprises a copolymer of ethylene and at least one monomer selected from the group consisting of propylene, butylene, and any combination thereof. 26. The biomedical device of one of claims 21-25 being at least one selected from the group consisting of a pump, tubing, a feeding tube, a catheter, a vascular catheter, a stent, a heart valve, a stomach ring, a surgical instrument, a nasopharyngeal implant, and a laryngeal implant, a drug delivery device, an intrauterine device, and an intravaginal ring. 27. The biomedical device of one of claims 21-26 further comprising: at least one wire disposed within the internal volume. 28. The biomedical device of claim 27 being at least one selected from the group consisting of a pacemaker, a neurostimulator, and a cochlear implant. 29. A kit comprising the biomedical device of one of claims 21-28 and a set of instructions. 30. A method comprising: implanting the biomedical device of one of claims 21-29 into a patient. 31. A method comprising: treating a patient with the biomedical device of one of claims 21- 30. 32. A method comprising: providing a polyethylene composition melt that comprises polyethylene having a melt flow index of about 3.5 g/10 min or greater as measured by ASTM D1238 at 190°C/21.5 kg weight and having an ash content of about 500 ppm or less; and extruding the polyethylene composition melt to form a molded polyethylene component of a biomedical device. 33. The method of claim 32, wherein the polyethylene composition melt further comprises an additive that comprises at least one selected from the group consisting of a plasticizer, a compatibilizer, an active pharmaceutical ingredient, a contrast agent, an antioxidant, a reinforcing filler, a pigment, a dye, a radioopaque filler, a lubricant, a processing aid, a light stabilizer, a neutralizer, an antiblock, and any combination thereof. 34. The method of one of claims 32-33, wherein the polyethylene composition melt further comprises at least one second polymer selected from the group consisting of a polyethylene, linear low density polyethylenes, low density polyethylenes, a polypropylene, a graft- modified olefin polymer, a chlorinated polyethylene, a thermoplastic vulcanizate, a polyether ether ketone, a polyisoprene, a polyester, a polyamide, an ethylene vinyl acetate copolymer, an ethylene vinyl-methacrylate copolymer, a silicone, a polyethylene glycol, poly lactic acid, poly glycolic acid, polyethylene imine, a polyurethane, polyacrylonitrile, a styrene block copolymer, a rubber, an ethylene-carboxylic acid copolymer, an ethylene acrylate copolymer, polybutylene, polybutadiene, a nylon, a polycarbonate, an ethylene ethylacrylate polymer, an ethylene styrene interpolymer, any derivative thereof, any copolymer thereof, and any combination thereof. 35. The method of one of claims 32-34, wherein the polyethylene composition is extruded onto at least a portion of a surface of the reinforcing structure. 36. The method of one of claims 32-35 further comprising: applying to the molded polyethylene component at least one selected from the group consisting of an active pharmaceutical ingredient, a contrast agent, an antioxidant, a pigment, a dye, a radioopaque filler, a lubricant, a processing aid, a light stabilizer, a neutralizer, an antiblock, and any combination thereof. 37. The method of one of claims 32-36 further comprising: assembling the biomedical device comprising the molded polyethylene component. 38. The method of one of claims 32-37', wherein the biomedical device is at least one selected from the group consisting of a chip, an RFID tag, tubing, a pump, a feeding tube, a catheter, a vascular catheter, a prosthetic, an inflatable balloon, a stent, a heart valve, a neurostimulator, a cochlear implant, a cranio-maxillofacial implant, synthetic cartilage, a stomach ring, a surgical instrument, a blood vessel clamp, an aneurysm clip, a spinal plug for use in conjunction with a joint fusion system, a base-plate stem cap for an artificial joint, a muscle implant, a nasopharyngeal implant, a laryngeal implant, a drug delivery device, a transdermal patch, a subdermal implant, an oromucosal insert, an intrauterine device, an intravaginal ring, and a dental fiber. 39. A method comprising: providing a polyethylene composition melt that comprises polyethylene having a melt flow index of about 3.5 g/10 min or greater as measured by ASTM D1238 at 190°C/21.5 kg weight and having an ash content of about 500 ppm or less; and injection molding the polyethylene composition melt to form a molded polyethylene component of a biomedical device. 40. A method comprising: providing a component of a biomedical device; and substantially encasing the component in polyethylene having a melt flow index of about 3.5 g/10 min or greater as measured by ASTM D1238 at 190°C/21.5 kg weight and having an ash content of about 500 ppm or less. 41. The method of claim 40, wherein substantially encasing involves over molding. 42. The method of one of claims 40-41, wherein the component is a wire. 43. A method comprising: polymerizing at least one olefin in the presence of a catalyst so as to form polyethylene having a melt flow index of about 3.5 g/10 min or greater as measured by ASTM D1238 at 190°C/21.5 kg weight, the at least one olefin comprising ethylene and optionally at least one selected from the group consisting of propylene, butylene, and any combination thereof; and treating the polyethylene to yield a treated polyethylene having an ash content of about 500 ppm or less. 44. The method of claim 43 further comprising: forming a molded polyethylene component of a biomedical device from the treated polyethylene. 45. The method of one of claims 43-44 wherein treating involves exposing the polyethylene concurrently or in series to at least one selected from the group consisting of steam, an inert solvent the catalyst is at least partially soluble in, an acid, acetone, water, a halogenated solvent, and any combination thereof. 46. The method of claim 45, wherein treating further involves increased temperature and/or decreased pressure. 47. A method comprising: providing a sheet comprising a polyethylene composition that comprises polyethylene having a melt flow index of about 3.5 g/10 min or greater as measured by ASTM D1238 at 190°C/21.5 kg weight and having an ash content of about 500 ppm or less; and thermoforming the sheet into a molded polyethylene component of a biomedical device. 48. A method comprising: providing a sheet comprising a polyethylene composition that comprises polyethylene having a melt flow index of about 3.5 g/10 min or greater as measured by ASTM D1238 at 190°C/21.5 kg weight and having an ash content of about 500 ppm or less; and shrink wrapping the sheet onto a portion of a biomedical device or component thereof. INTERNATIONAL SEARCH REPORT International application No. PCT/US2013/054841 A. CLASSIFICATION OF SUBJECT MATTER A61L 33/06(2006.01)i, A61L 27/14(2006.01)i, A61M 25/01(2006.01)i, A61F 2/82(2006.01)i

According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) A61L 33/06; B32B 1/08; A61F 2/28; B32B 7/02; A61F 13/00; C O8F 4/42; C08F 110/02; A61K 38/18; B65D 30/02; C08F 210/00; A61L 27/14; A61M 25/01; A61F 2/82

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Korean utility models and applications for utility models Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) eKOMPASS(KIPO internal) & Keywords: biomedical device, polyethylene, ash, melt flow index

DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.

Y US 5372819 A (GODBEY e t al.) 13 December 1994 1-3,21-23,32-34 see claim 1 ; columns 3-7. ,39-48

US 2011-0262670 A l (KOKKO e t al.) 27 October 2011 1-3,21-23,32-34 see claims 1-3 and 12-14; paragraphs [0107] and [0131]. ,39-48

US 2010-0215718 A l (SWORDS e t al.) 26 August 2010 1-3,21-23,32-34 see the whole document. ,39-48

US 4775562 A (SHISHIDO e t al.) 04 October 1988 1-3,21-23,32-34 see the whole document. ,39-48

US 6476171 Bl (LUE e t al.) 05 November 2002 1-3,21-23,32-34 see the whole document. ,39-48

I IFurther documents are listed in the continuation of Box C. See patent family annex.

Special categories of cited documents: later document published after the international filing date or priority document defining the general state of the art which is not considered date and not in conflict with the application but cited to understand to be of particular relevance the principle or theory underlying the invention earlier application or patent but published on or after the international document of particular relevance; the claimed invention cannot be filing date considered novel or cannot be considered to involve an inventive document which may throw doubts on priority claim(s) or which is step when the document is taken alone cited to establish the publication date of citation or other document of particular relevance; the claimed invention cannot be special reason (as specified) considered to involve an inventive step when the document is document referring to an oral disclosure, use, exhibition or other combined with one or more other such documents, such combination means being obvious to a person skilled in the art document published prior to the international filing date but later document member of the same patent family than the priority date claimed Date of the actual completion of the international search Date of mailing of the international search report 12 November 2013 (12. 11.2013) 13 November 2013 (13.11.2013)

Name and mailing address of the ISA KR Authorized officer Korean Intellectual Property Office 189 Cheongsa-ro, Seo-gu, Daejeon Metropolitan City, K V , Seung Beom 302-701, Republic of Korea Facsimile No. +82-42-472-7140 Telephone No. +82-42-481-3371 Form PCT/ISA/210 (second sheet) ( y 2009) INTERNATIONAL SEARCH REPORT International application No. PCT/US2013/054841

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons

Claims Nos.: 19-20, 30-3 1 because they relate to subject matter not required to be searched by this Authority, namely: Claims 19-20, 30-3 1 pertain to methods for treatment of the human body by surgery, and thus relate to a subject matter which this International Searching Authority is not required, under Article 17(2)(a)(i) of the PCT and Rule 39. 1(iv) of the Regulations under the PCT, to search.

Claims Nos.: 15,28 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically : Claims 15,28 are unclear since they are referring to the multiple dependent claims which do not comply with PCT Rule 6.4(a).

Claims Nos.: 4-14,16-20,24-27,29-3 1,35-38 because t ey are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. Ill Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

I IAs all required addtional search fees were timely paid by the applicant, this international search report covers all searchable claims.

I IAs all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

I IAs only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos. :

4. I INo required additional search fees were timely paid by the applicant. Consequently, this international search report restricted to the invention first mentioned in t e claims; it is covered by claims Nos. :

Remark on Protest | | The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee. I IThe additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation. I INo protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (2)) (July 2009) INTERNATIONAL SEARCH REPORT International application No. Information on patent family members PCT/US2013/054841

Patent document Publication Patent family Publication cited in search report date member(s) date

US 05372819 A 13/12/1994 DE 69314650 Dl 20/11/1997 DE 69314650 T2 26/03/1998 EP 0654065 Al 24/05/1995 EP 0654065 Bl 15/10/1997 JP 03455219 B2 14/10/2003 JP 08-500139 A 09/01/1996 US 05264219 A 23/11/1993 o 94-03539 Al 17/02/1994

US 2011-0262670 Al 27/10/2011 CA 2741960 Al 06/05/2010 CN 102216342 A 12/10/2011 EP 2350140 Al 03/08/2011 R 10-2011-0090981 A 10/08/2011 O 2010-049169 Al 06/05/2010

US 2010-0215718 Al 26/08/2010 EP 2401000 A2 04/01/2012 WO 2010-099333 A2 02/09/2010 wo 2010-099333 A3 26/05/2011

US 04775562 A 04/10/1988 DE 3681536 Dl 24/10/1991 EP 0216509 A2 01/04/1987 EP 0216509 A3 24/08/1988 EP 0216509 Bl 18/09/1991 JP 03031062 B 02/05/1991 JP 04011220 B 27/02/1992 JP 62-044256 A 26/02/1987 JP 62-064363 A 23/03/1987

US 6476171 Bl 05/11/2002 AR 012220 Al 27/09/2000 AU 6781798 A 22/10/1998 AU 733306 B2 10/05/2001 BR 9807852 A 22/02/2000 CA 2283246 Al 08/10/1998 CA 2283246 C 05/08/2008 CN 1111550 C 18/06/2003 CN 1272853 A 08/11/2000 DE 69819314 Dl 04/12/2003 DE 69819314 T2 26/08/2004 EA 002321B1 25/04/2002 EP 0973814 Al 26/01/2000 EP 0973814 Bl 29/10/2003 JP 04982003 B2 25/07/2012 JP 2002-513437 A 08/05/2002 T W 422853 B 21/02/2001 us 6255426 Bl 03/07/2001 wo 98-44011A1 08/10/1998 ZA 9802690 A 16/03/1999

Form PCT/ISA/210 (patent family annex) ( y 2009)